Trilayer coated pharmaceutical packaging with low oxygen transmission rate

ABSTRACT

An article is described including an article surface and a coating set comprising an optional tie coating or layer, a barrier coating or layer, and a pH protective layer. The respective coatings or layers can be applied by chemical vapor deposition of a polysiloxane or polysilazane precursor in the presence of oxygen. Examples of such an article are a prefilled thermoplastic syringe or thermoplastic pharmaceutical vial with a coated interior portion containing a pharmaceutical preparation or other fluid with a pH of 4 to 8, alternatively 5 to 9. The barrier coating or layer prevents oxygen from penetrating into the thermoplastic syringe or vial. The tie coating or layer, if present, and the pH protective coating or layer protect the barrier layer from the contents of the syringe or vial.

This application is a continuation-in-part of U.S. Ser. No. 14/205,329,filed Mar. 11, 2014, which claims priority to U.S. ProvisionalApplications 61/776,733, filed Mar. 11, 2013, and 61/800,746, filed Mar.15, 2013. The entire specification and all the drawings of each of theseapplications are incorporated here by reference to provide continuity ofdisclosure.

The specification and drawings of U.S. Pat. No. 7,985,188 areincorporated here by reference in their entirety. That patent describesapparatus, vessels, precursors, coatings or layers and methods (inparticular coating methods and test methods for examining the coatingsor layers) which can generally be used in performing the presentinvention, unless stated otherwise herein. They also describe SiO_(x)barrier coatings or layers to which reference is made herein.

FIELD OF THE INVENTION

The present invention relates to the technical field of barrier coatedsurfaces, for example interior surfaces of pharmaceutical packages orother vessels for storing or other contact with fluids. Examples ofsuitable fluids include foods, nutritional supplements, drugs,inhalation anaesthetics, diagnostic test materials, or biologicallyactive compounds or body fluids, for example blood. The presentinvention also relates to a pharmaceutical package or other vessel andto a method for making a pharmaceutical package with a pH protectivecoating or layer between the contents and the barrier coating or layer.The present invention also relates more generally to medical articles,including articles other than packages or vessels, for examplecatheters.

The present disclosure also relates to improved methods for processingpharmaceutical packages or other vessels, for example multiple identicalpharmaceutical packages or other vessels used for pharmaceuticalpreparation storage and delivery, venipuncture and other medical samplecollection, and other purposes.

The resulting packages are also claimed. Such pharmaceutical packages orother vessels are used in large numbers for these purposes, and must berelatively economical to manufacture and yet highly reliable in storageand use.

BACKGROUND OF THE INVENTION

One important consideration in manufacturing pharmaceutical packages orother vessels for storing or other contact with fluids, for examplevials and pre-filled syringes, is that the contents of thepharmaceutical package or other vessel desirably will have a substantialshelf life. During this shelf life, it is important to isolate thematerial filling the pharmaceutical package or other vessel from thevessel wall containing it, or from barrier layers or other functionallayers applied to the pharmaceutical package or other vessel wall toavoid leaching material from the pharmaceutical package or other vesselwall, barrier layer, or other functional layers into the prefilledcontents or vice versa.

Some companies have turned to plastic pharmaceutical packages or othervessels, which provide greater dimensional tolerance and less breakagethan glass, but its use for primary pharmaceutical packaging remainslimited due to its gas (oxygen) permeability: Plastic allows smallmolecule gases to permeate into (or out of) the article. Thepermeability of plastics to gases is significantly greater than that ofglass and, in many cases (as with oxygen-sensitive drugs such asepinephrine), plastics have been unacceptable for that reason.

The problem of permeability has been addressed by adding a barriercoating or layer to the plastic pharmaceutical package where it contactsfluid contents of the package. One such barrier layer is a very thincoating of SiO_(x), as defined below, applied by plasma enhancedchemical vapor deposition. But, current SiO_(x) barrier layers depositedon a package by PECVD are etched off by aqueous contents of the packagehaving pH-values greater than 4, particularly at higher pH values. Thisreduces the useful shelf life of the package as its barrier efficacy isreduced.

SUMMARY OF THE INVENTION

An aspect of the invention is a pharmaceutical package comprising athermoplastic wall defining a lumen; a coating set on the interiorsurface of the thermoplastic wall; and a fluid contained in the lumen.The thermoplastic wall has an interior surface facing the lumen. Thethermoplastic wall has a first oxygen transmission rate respectingingress of oxygen.

The coating set on the interior surface comprises an optional tiecoating or layer, a barrier coating or layer, and a pH protectivecoating or layer. The optional tie coating or layer has an interiorsurface facing the lumen and an outer surface facing the wall interiorsurface. The barrier coating or layer has an outer surface facing thewall interior surface and, if present, the interior surface of theoptional tie coating or layer. The pH protective coating or layer has aninterior surface facing the lumen and an outer surface facing theinterior surface of the barrier coating or layer. The barrier coating orlayer is effective to provide a second oxygen transmission rate lowerthan the first oxygen transmission rate.

The fluid contained in the lumen has a pH from 3 to 9. The coating seton the interior surface is effective to maintain the second oxygentransmission rate lower than the first oxygen transmission rate for atleast six months after initial contact between the fluid in the lumenand the pH protective coating or layer.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic sectional view of a vessel according to anyembodiment of the invention.

FIG. 2 is an enlarged detail view of a portion of the vessel wall andcoatings of FIG. 1.

FIG. 3 is a schematic view of a pharmaceutical package in the form of asyringe barrel as the vessel of FIGS. 1 and 2, containing a fluid andclosed with a closure in the form of a plunger.

FIG. 4 is a schematic view of a pharmaceutical package in the form of avial as the vessel of FIGS. 1 and 2 containing a fluid and closed with aclosure.

FIG. 5 is a schematic view of a pharmaceutical package in the form of ablister package as the vessel of FIGS. 1 and 2 containing a fluid andclosed with a closure in the form of a coated sheet defining anadditional vessel wall.

FIG. 6 is a plot of silicon dissolution versus exposure time at pH 6 fora glass container versus a plastic container having an SiO_(x) barrierlayer coated in the inside wall.

FIG. 7 is a schematic view of a syringe with a trilayer coatingaccording to FIGS. 1, 2, and 3, showing a cylindrical region andspecific points where data was taken.

FIG. 8 is a Trimetric map of the overall trilayer coating thicknessversus position in the cylindrical region of a syringe illustrated byFIGS. 7, 1, 2, and 3.

FIG. 9 is a photomicrograhic sectional view showing the substrate andcoatings of the trilayer coating at position 2 shown in FIG. 7.

FIG. 10 is another Trimetric map of the overall trilayer coatingthickness versus position in the cylindrical region of another syringeillustrated by FIGS. 7, 1, 2, and 3.

FIG. 11 is a plot of coating thickness, representing the same coating asFIG. 10, at Positions 1, 2, 3, and 4 shown in FIG. 7.

FIG. 12 is a longitudinal section view of a vial, schematically showingthe gas inlet and external electrode of the coating apparatus andindexed to show ten locations where data was taken.

FIG. 13 is a photograph showing the benefit of the present trilayercoating in preventing pinholes after attack by an alkaline reagent, asdiscussed in the working examples.

FIG. 14 is an enlarged detail view of the indicated portion of FIG. 13.

The following reference characters are used in the drawing figures:

210 Pharmaceutical package 212 Lumen 214 Wall 216 Outer surface 218Fluid 220 Interior surface (of 288) 222 Outer surface (of 288) 224Interior surface (of 286) 226 Outer surface (of 286) 250 Syringe barrel254 Inner or interior surface (of 250) 256 Back end (of 250) 258 Plunger(of 252) (relatively sliding part) 260 Front end (of 250) 262 Closure285 Vessel coating or layer set 286 pH protective coating or layer 288Barrier layer 289 Tie coating or layer

In the context of the present invention, the following definitions andabbreviations are used:

RF is radio frequency.

The term “at least” in the context of the present invention means “equalor more” than the integer following the term. The word “comprising” doesnot exclude other elements or steps, and the indefinite article “a” or“an” does not exclude a plurality unless indicated otherwise. Whenever aparameter range is indicated, it is intended to disclose the parametervalues given as limits of the range and all values of the parameterfalling within said range.

“First” and “second” or similar references to anything refer to theminimum number of such things that are present, but do not necessarilyrepresent the order or total number of such things or require additionalsuch things beyond the stated number. For example, a “first” deposit inthe context of this specification can be either the only deposit or anyone of plural deposits, without limitation. In other words, recitationof a “first” deposit allows but does not require an embodiment that alsohas a second or further deposit.

For purposes of the present invention, an “organosilicon precursor” is acompound having at least one of the linkages:

which is a tetravalent silicon atom connected to an oxygen or nitrogenatom and an organic carbon atom (an organic carbon atom being a carbonatom bonded to at least one hydrogen atom). A volatile organosiliconprecursor, defined as such a precursor that can be supplied as a vaporin a PECVD apparatus, is an optional organosilicon precursor.Optionally, the organosilicon precursor is selected from the groupconsisting of a linear siloxane, a monocyclic siloxane, a polycyclicsiloxane, a polysilsesquioxane, an alkyl trimethoxysilane, a linearsilazane, a monocyclic silazane, a polycyclic silazane, apolysilsesquiazane, and a combination of any two or more of theseprecursors.

The feed amounts of PECVD precursors, gaseous reactant or process gases,and carrier gas are sometimes expressed in “standard volumes” in thespecification and claims. The standard volume of a charge or other fixedamount of gas is the volume the fixed amount of the gas would occupy ata standard temperature and pressure (without regard to the actualtemperature and pressure of delivery). Standard volumes can be measuredusing different units of volume, and still be within the scope of thepresent disclosure and claims. For example, the same fixed amount of gascould be expressed as the number of standard cubic centimeters, thenumber of standard cubic meters, or the number of standard cubic feet.Standard volumes can also be defined using different standardtemperatures and pressures, and still be within the scope of the presentdisclosure and claims. For example, the standard temperature might be 0°C. and the standard pressure might be 760 Torr (as is conventional), orthe standard temperature might be 20° C. and the standard pressure mightbe 1 Torr. But whatever standard is used in a given case, when comparingrelative amounts of two or more different gases without specifyingparticular parameters, the same units of volume, standard temperature,and standard pressure are to be used relative to each gas, unlessotherwise indicated.

The corresponding feed rates of PECVD precursors, gaseous reactant orprocess gases, and carrier gas are expressed in standard volumes perunit of time in the specification. For example, in the working examplesthe flow rates are expressed as standard cubic centimeters per minute,abbreviated as sccm. As with the other parameters, other units of timecan be used, such as seconds or hours, but consistent parameters are tobe used when comparing the flow rates of two or more gases, unlessotherwise indicated.

A “vessel” in the context of the present invention can be any type ofvessel with at least one opening and a wall defining an inner orinterior surface. The substrate can be the wall of a vessel having alumen. Though the invention is not necessarily limited to pharmaceuticalpackages or other vessels of a particular volume, pharmaceuticalpackages or other vessels are contemplated in which the lumen has a voidvolume of from 0.5 to 250 mL, optionally from 1 to 10 mL, optionallyfrom 0.5 to 5 mL, optionally from 1 to 3 mL. The substrate surface canbe part or all of the inner or interior surface of a vessel having atleast one opening and an inner or interior surface. Some examples of apharmaceutical package include, but are not limited to, a vial, aplastic-coated vial, a syringe, a plastic coated syringe, a blisterpack, an ampoule, a plastic coated ampoule, a cartridge, a bottle, aplastic coated bottle, a pouch, a pump, a sprayer, a stopper, a needle,a plunger, a cap, a stent, a catheter or an implant.

Additionally, a vessel according to the present invention can be asample tube, for example for collecting or storing biological fluidslike blood or urine, a syringe part, for example a syringe barrel, forstoring or delivering a biologically active compound or composition, forexample a medicament or pharmaceutical composition, a vial for storingbiological materials or biologically active compounds or compositions, apipe or tubing, for example a catheter for transporting biologicalmaterials or biologically active compounds or compositions, or a cuvettefor holding fluids, for example for holding biological materials orbiologically active compounds or compositions.

A vessel can be of any shape. A vessel having a substantiallycylindrical wall adjacent to at least one of its open ends is preferred.Generally, the interior wall of the vessel is cylindrically shaped,like, for example in a sample tube or a syringe barrel.

Sample tubes and syringes or their parts (for example syringe barrels)are contemplated.

The values of w, x, y, and z are applicable to the empirical compositionSi_(w)O_(x)C_(y)H_(z) throughout this specification, and the same valuesof x and y are applicable to the empirical composition SiO_(x)C_(y)throughout this specification. The values of w, x, y, and z usedthroughout this specification should be understood as ratios or anempirical formula (for example for a coating or layer), rather than as alimit on the number or type of atoms in a molecule. For example,octamethylcyclotetrasiloxane, which has the molecular compositionSi₄O₄C₈H₂₄, can be described by the following empirical formula, arrivedat by dividing each of w, x, y, and z in the molecular formula by 4, thelargest common factor: Si₁O₁C₂H₆. The values of w, x, y, and z are alsonot limited to integers. For example, (acyclic) octamethyltrisiloxane,molecular composition Si₃O₂C₈H₂₄, is reducible to Si₁O_(0.67)C_(2.67)H₈.

The atomic ratio of Si_(w)O_(x)C_(y)H_(z) can be determined by XPS,except that H atoms are not detectable by XPS. Hydrogen atoms are,however, detectable using a different analysis, for example RutherfordBackscattering or Rutherford Forward Scattering. A particular coating orlayer may thus in one aspect be expressed by the formulaSi_(w)O_(x)C_(y)H_(z), for example where w is 1, x is from about 0.5 toabout 2.4, y is from about 0.6 to about 3, and z is from about 2 toabout 9. The same particular coating or layer can alternatively becharacterized by XPS only, without accounting for hydrogen, and thusexpressed by the formula SiO_(x)C_(y), in which x is from about 0.5 toabout 2.4 and y is from about 0.6 to about 3. SiO_(x)C_(y), has nosubscript following Si, which has the same meaning as a subscript w of 1in the formula Si_(w)O_(x)C_(y)H_(z). In this specification, XPS isgenerally used without accounting for hydrogen, and the atomic ratio isexpressed as SiO_(x)C_(y). Typically, such coating or layer would hencecontain 36% to 41% carbon normalized to 100% carbon plus oxygen plussilicon.

The term “syringe” is broadly defined to include cartridges, injection“pens,” and other types of barrels or reservoirs adapted to be assembledwith one or more other components to provide a functional syringe.“Syringe” is also broadly defined to include related articles such asauto-injectors, which provide a mechanism for dispensing the contents.

DETAILED DESCRIPTION

The present invention will now be described more fully, with referenceto the accompanying drawings, in which several embodiments are shown.This invention can, however, be embodied in many different forms andshould not be construed as limited to the embodiments set forth here.Rather, these embodiments are examples of the invention, which has thefull scope indicated by the language of the claims. Like numbers referto like or corresponding elements throughout. The following disclosurerelates to all embodiments unless specifically limited to a certainembodiment.

Vessels and Coating Sets

An aspect of the invention, illustrated most broadly by FIG. 1 and thedetail view of FIG. 2, is a vessel 210 including a wall 214 enclosing alumen 212 and a vessel coating or layer set 285 on at least a portion ofthe wall 214 facing the lumen 212. The vessel may be more specifically avial, a syringe, a blister pack, an ampoule, a cartridge, a bottle, apouch, a pump, a sprayer, a stopper, a needle, a plunger, a cap, astent, a catheter or an implant, or any other type of container orconduit for a fluid. FIGS. 1 through 5 show a vessel having at least asingle opening, and should be understood to include a vessel having twoor more openings, such as a syringe, or a vessel having no openings,such as a pouch, blister pack, or ampoule.

An embodiment of the vessel coating or layer set 285 is at least one tiecoating or layer 289 (which is optional), at least one barrier coatingor layer 288, and at least one pH protective coating or layer 286,illustrated in FIGS. 1, 2. This embodiment of the vessel coating orlayer set is sometimes known as a “trilayer coating” in which thebarrier coating or layer 288 of SiO_(x) is protected against contentshaving a pH otherwise high enough to remove it by being sandwichedbetween the pH protective coating or layer 286 and the tie coating orlayer 289, each an organic layer of SiO_(x)C_(y) as defined in thisspecification. A specific example of this trilayer coating is providedin this specification. The contemplated thicknesses of the respectivelayers in nm (preferred ranges in parentheses) are given in the TrilayerThickness Table 1.

Trilayer Thickness Table 1 Adhesion Barrier Protection  5-100  20-200 50-500 (5-20) (20-30) (100-200)

Several particular coordinating coating sets 285, 285 a, and 285 b for avessel 210 and closure of FIG. 1 are shown in Table 2 of Coating Sets:

Table 2 of Coating Sets Vessel wall Closure sliding Closure facing Set(285) surface (285a) surface (285b) 1 pH protective (286) Lubricity(281) e.g. Barrier (288) - e.g. barrier (288) Parylene. Parylene tie(289) Sliding surface of Facing surface of syringe barrel wall closure,e.g. closure, e.g. (214) plunger tip plunger tip. 2 Lubricant deposit Nocoating set 285a pH protective (286) (287) Sliding surface of barrier(288) SiO_(x) primer (283) closure, e.g. Facing surface of pH protective(286) plunger tip closure barrier (288) tie (289) syringe barrel wall(214) 3 pH protective (286) Lubricity (281) e.g. Barrier (288) - e.g.barrier (288) Parylene. Parylene syringe barrel wall Sliding surface ofFacing surface of (214) closure, e.g. closure, e.g. plunger tip plungertip. 4 SiO_(x) primer (283) Lubricity (281) e.g. pH protective (286) pHprotective (286) SiO_(x)C_(y) barrier (288) barrier (288) Slidingsurface of Facing surface of syringe barrel wall closure, e.g. closure(214) plunger tip 5 pH protective (286) Lubricant deposit Lubricantdeposit barrier (288) (287) (287) Vial wall (214) Sliding surface ofFacing surface of closure (e.g. closure (e.g. septum) septum) 6 pHprotective (286) Lubricant deposit Lubricant deposit barrier (288) (287)(287) tie (289) Sliding surface of Facing surface of Vial wall (214)closure (e.g. closure (e.g. septum) septum) 7 Lubricity (281) e.g.Barrier (288) - e.g. Barrier (288) - e.g. SiO_(x)C_(y) Parylene ParylenepH protective (286) barrier (288) tie (289) Vial wall (214)

Sets 1-4 and 7 in Table 2 of Coating Sets are among the usefulalternatives for a syringe. The syringe barrel wall coatings (leftcolumn) of Set 1 are one example of the previously described trilayercoating, and Set 7 is a modification of the trilayer coating in which aPECVD lubricant coating or layer is the top layer of the set.

The Set 1 trilayer coating set 285, illustrated in FIG. 2, is applied toa COP syringe barrel in one embodiment.

The Set 1 trilayer coating set 285 optionally includes as a first layeran adhesion or tie coating or layer 289 that improves adhesion of thebarrier coating or layer to the COP substrate. The adhesion or tiecoating or layer 289 is also believed to relieve stress on the barriercoating or layer 288, making the barrier layer less subject to damagefrom thermal expansion or contraction or mechanical shock. The adhesionor tie coating or layer 289 is also believed to decouple defects betweenthe barrier coating or layer 288 and the COP substrate. This is believedto occur because any pinholes or other defects that may be formed whenthe adhesion or tie coating or layer 289 is applied tend not to becontinued when the barrier coating or layer 288 is applied, so thepinholes or other defects in one coating do not line up with defects inthe other. The adhesion or tie coating or layer 289 has some efficacy asa barrier layer, so even a defect providing a leakage path extendingthrough the barrier coating or layer 289 is blocked by the adhesion ortie coating or layer 289.

The Set 1 trilayer coating set 285 includes as a second layer a barriercoating or layer 288 that provides a barrier to oxygen that haspermeated the COP barrel wall. The barrier coating or layer 288 also isa barrier to extraction of the composition of the barrel wall 214 by thecontents of the lumen 214.

The Set 1 trilayer coating set 285 includes as a third layer a pHprotective coating or layer 286 that provides protection of theunderlying barrier coating or layer 288 against contents of the syringehaving a pH from 4 to 8, including where a surfactant is present. For aprefilled syringe that is in contact with the contents of the syringefrom the time it is manufactured to the time it is used, the pHprotective coating or layer 286 prevents or inhibits attack of thebarrier coating or layer 288 sufficiently to maintain an effectiveoxygen barrier over the intended shelf life of the prefilled syringe.

The pH protective coating or layer 286 optionally provides protection ofthe underlying barrier coating or layer 288 against contents of a vessel210 having a pH from 4 to 8, including where a surfactant is present.For a prefilled pharmaceutical package that is in contact with thecontents of the lumen 212 from the time it is manufactured to the timeit is used, the pH protective coating or layer 286 optionally preventsor inhibits attack of the barrier coating or layer 288 sufficiently tomaintain an effective oxygen barrier over the intended shelf life of theprefilled syringe. The rate of erosion, dissolution, or leaching(different names for related concepts) of the pH protective coating orlayer 286, if directly contacted by a fluid, is less than the rate oferosion of the barrier coating or layer 288, if directly contacted bythe fluid having a pH of from 5 to 9. The pH protective coating or layer286 is effective to isolate a fluid 218 having a pH between 5 and 9 fromthe barrier coating or layer 288, at least for sufficient time to allowthe barrier coating to act as a barrier during the shelf life of thepharmaceutical package or other vessel 210.

Sets 5 and 6 are useful for a vial, for instance. The lubricant depositas the coating set 285 b represents a siliconized septum in which theentire surface is coated with a lubricant to aid insertion into a vialneck, so the facing surface of the closure is coated although thecoating is not needed there.

The vessel wall coating set 285 represented by Set 6 is another trilayercoating set, again illustrated in FIG. 2, applied to a COP vial in oneembodiment. The trilayer coating has the same layers and provides thesame performance as the syringe trilayer coating of Set 1 describedabove.

Certain syringes prefilled with synthetic and biological pharmaceuticalformulations are very oxygen and moisture sensitive. A critical factorin the conversion from glass to plastic syringe barrels will be theimprovement of plastic oxygen and moisture barrier performance. Theplasma primer coating or layer technology is suitable to maintain theSiO_(x) barrier coating or layer for protection against oxygen andmoisture over an extended shelf life.

Oxygen transmission rate (OTR) is deemed appropriate to verify integrityof barrier coatings.

Tie Coating or Layer

The optional tie coating or layer 289 has at least two functions. Onefunction of the tie coating or layer 289 is to improve adhesion of abarrier coating or layer 288 to a substrate, in particular athermoplastic substrate, although a tie layer can be used to improveadhesion to a glass substrate or to another coating or layer. Forexample, a tie coating or layer, also referred to as an adhesion layeror coating can be applied to the substrate and the barrier layer can beapplied to the adhesion layer to improve adhesion of the barrier layeror coating to the substrate.

Another function of the tie coating or layer 289 has been discovered: atie coating or layer 289 applied under a barrier coating or layer 288can improve the function of a pH protective coating or layer 286 appliedover the barrier coating or layer 288.

The tie coating or layer 289 can be composed of, comprise, or consistessentially of SiO_(x)C_(y), in which x is between 0.5 and 2.4 and y isbetween 0.6 and 3. The atomic ratios of Si, O, and C in the tie coatingor layer 289 are, as several options:

Si 100:O 50-150:C 90-200 (i.e. w=1, x=0.5 to 1.5, y=0.9 to 2);

Si 100:O 70-130:C 90-200 (i.e. w=1, x=0.7 to 1.3, y=0.9 to 2)

Si 100:O 80-120:C 90-150 (i.e. w=1, x=0.8 to 1.2, y=0.9 to 1.5)

Si 100:O 90-120:C 90-140 (i.e. w=1, x=0.9 to 1.2, y=0.9 to 1.4), or

Si 100:O 92-107:C 116-133 (i.e. w=1, x=0.92 to 1.07, y=1.16 to 1.33)

The atomic ratio can be determined by XPS.

Optionally, the tie coating or layer can be similar or identical incomposition with the pH protective coating or layer 286 describedelsewhere in this specification, although this is not a requirement.

The tie coating or layer 289 is contemplated in any embodiment generallyto be from 5 nm to 100 nm thick, preferably from 5 to 20 nm thick,particularly if applied by chemical vapor deposition. These thicknessesare not critical. Commonly but not necessarily, the tie coating or layer289 will be relatively thin, since its function is to change the surfaceproperties of the substrate.

Barrier Layer

A barrier coating or layer 288 optionally can be deposited by plasmaenhanced chemical vapor deposition (PECVD) or other chemical vapordeposition processes on the vessel of a pharmaceutical package, inparticular a thermoplastic package, to prevent oxygen, carbon dioxide,or other gases from entering the vessel and/or to prevent leaching ofthe pharmaceutical material into or through the package wall.

The barrier coating or layer for any embodiment defined in thisspecification (unless otherwise specified in a particular instance) is acoating or layer, optionally applied by PECVD as indicated in U.S. Pat.No. 7,985,188. The barrier layer optionally is characterized as an“SiO_(x)” coating, and contains silicon, oxygen, and optionally otherelements, in which x, the ratio of oxygen to silicon atoms, is fromabout 1.5 to about 2.9, or 1.5 to about 2.6, or about 2. Thesealternative definitions of x apply to any use of the term SiO_(x) inthis specification. The barrier coating or layer is applied, for exampleto the interior of a pharmaceutical package or other vessel, for examplea sample collection tube, a syringe barrel, a vial, or another type ofvessel.

The barrier coating 288 comprises or consists essentially of SiO_(x),wherein x is from 1.5 to 2.9, from 2 to 1000 nm thick, the barriercoating 288 of SiO_(x) having an interior surface 220 facing the lumen212 and an outer surface 222 facing the wall 214 article surface 254,the barrier coating 288 being effective to reduce the ingress ofatmospheric gas into the lumen 212 compared to an uncoated vessel 250.One suitable barrier composition is one where x is 2.3, for example. Forexample, the barrier coating or layer such as 288 of any embodiment canbe applied at a thickness of at least 2 nm, or at least 4 nm, or atleast 7 nm, or at least 10 nm, or at least 20 nm, or at least 30 nm, orat least 40 nm, or at least 50 nm, or at least 100 nm, or at least 150nm, or at least 200 nm, or at least 300 nm, or at least 400 nm, or atleast 500 nm, or at least 600 nm, or at least 700 nm, or at least 800nm, or at least 900 nm. The barrier coating or layer can be up to 1000nm, or at most 900 nm, or at most 800 nm, or at most 700 nm, or at most600 nm, or at most 500 nm, or at most 400 nm, or at most 300 nm, or atmost 200 nm, or at most 100 nm, or at most 90 nm, or at most 80 nm, orat most 70 nm, or at most 60 nm, or at most 50 nm, or at most 40 nm, orat most 30 nm, or at most 20 nm, or at most 10 nm, or at most 5 nmthick. Ranges of 20-200 nm, optionally 20-30 nm, are contemplated.Specific thickness ranges composed of any one of the minimum thicknessesexpressed above, plus any equal or greater one of the maximumthicknesses expressed above, are expressly contemplated.

The thickness of the SiO_(x) or other barrier coating or layer can bemeasured, for example, by transmission electron microscopy (TEM), andits composition can be measured by X-ray photoelectron spectroscopy(XPS). The primer coating or layer described herein can be applied to avariety of pharmaceutical packages or other vessels made from plastic orglass, for example to plastic tubes, vials, and syringes.

A barrier coating or layer 286 of SiO_(x), in which x is between 1.5 and2.9, is applied by plasma enhanced chemical vapor deposition (PECVD)directly or indirectly to the thermoplastic wall 214 (for example a tiecoating or layer 289 can be interposed between them) so that in thefilled pharmaceutical package or other vessel 210 the barrier coating orlayer 286 is located between the inner or interior surface 220 of thethermoplastic wall 214 and the fluid 218.

The barrier coating or layer 286 of SiO_(x) is supported by thethermoplastic wall 214. The barrier coating or layer 286 as describedelsewhere in this specification, or in U.S. Pat. No. 7,985,188, can beused in any embodiment.

Certain barrier coatings or layers 286 such as SiO_(x) as defined herehave been found to have the characteristic of being subject to beingmeasurably diminished in barrier improvement factor in less than sixmonths as a result of attack by certain relatively high pH contents ofthe coated vessel as described elsewhere in this specification,particularly where the barrier coating or layer directly contacts thecontents. This issue can be addressed using a pH protective coating orlayer as discussed in this specification.

pH Protective Coating or Layer

The inventors have found that barrier layers or coatings of SiO_(x) areeroded or dissolved by some fluids, for example aqueous compositionshaving a pH above about 5. Since coatings applied by chemical vapordeposition can be very thin—tens to hundreds of nanometers thick—even arelatively slow rate of erosion can remove or reduce the effectivenessof the barrier layer in less time than the desired shelf life of aproduct package. This is particularly a problem for fluid pharmaceuticalcompositions, since many of them have a pH of roughly 7, or more broadlyin the range of 5 to 9, similar to the pH of blood and other human oranimal fluids. The higher the pH of the pharmaceutical preparation, themore quickly it erodes or dissolves the SiO_(x) coating. Optionally,this problem can be addressed by protecting the barrier coating or layer288, or other pH sensitive material, with a pH protective coating orlayer 286.

Optionally, the pH protective coating or layer 286 can be composed of,comprise, or consist essentially of Si_(w)O_(x)C_(y)H_(z) (or itsequivalent SiO_(x)C_(y)) or Si_(w)N_(x)C_(y)H_(z) or its equivalentSi(NH)_(x)C_(y)). The atomic ratio of Si:O:C or Si:N:C can be determinedby XPS (X-ray photoelectron spectroscopy). The pH protective coating orlayer may thus in one aspect have the formula SiO_(x)C_(y), where x isfrom about 0.5 to about 2.4 and y is from about 0.6 to about 3. The samepH protective coating or layer may thus in another aspect have theformula SiO_(x)C_(y)H_(z), where x is from about 0.5 to about 2.4 and yis from about 0.6 to about 3, and z is from about 2 to about 9.

Typically, expressed as the formula Si_(w)O_(x)C_(y), where w=1, theatomic ratios of Si, O, and C are, as several options:

-   -   Si 100:O 50-150:C 90-200 (i.e. w=1, x=0.5 to 1.5, y=0.9 to 2);    -   Si 100:O 70-130:C 90-200 (i.e. w=1, x=0.7 to 1.3, y=0.9 to 2)    -   Si 100:O 80-120:C 90-150 (i.e. w=1, x=0.8 to 1.2, y=0.9 to 1.5)    -   Si 100:O 90-120:C 90-140 (i.e. w=1, x=0.9 to 1.2, y=0.9 to 1.4)    -   Si 100:O 92-107:C 116-133 (i.e. w=1, x=0.92 to 1.07, y=1.16 to        1.33), or    -   Si 100:O 80-130:C 90-150.

Alternatively, the pH protective coating or layer can have atomicconcentrations normalized to 100% carbon, oxygen, and silicon, asdetermined by X-ray photoelectron spectroscopy (XPS) of less than 50%carbon and more than 25% silicon. Alternatively, the atomicconcentrations are from 25 to 45% carbon, 25 to 65% silicon, and 10 to35% oxygen. Alternatively, the atomic concentrations are from 30 to 40%carbon, 32 to 52% silicon, and 20 to 27% oxygen. Alternatively, theatomic concentrations are from 33 to 37% carbon, 37 to 47% silicon, and22 to 26% oxygen.

The thickness of the pH protective coating or layer can be, for example,from 10 nm to 1000 nm; alternatively from 10 nm to 1000 nm;alternatively from 10 nm to 900 nm; alternatively from 10 nm to 800 nm;alternatively from 10 nm to 700 nm; alternatively from 10 nm to 600 nm;alternatively from 10 nm to 500 nm; alternatively from 10 nm to 400 nm;alternatively from 10 nm to 300 nm; alternatively from 10 nm to 200 nm;alternatively from 10 nm to 100 nm; alternatively from 10 nm to 50 nm;alternatively from 20 nm to 1000 nm; alternatively from 50 nm to 1000nm; alternatively from 10 nm to 1000 nm; alternatively from 50 nm to 800nm; alternatively from 100 nm to 700 nm; alternatively from 300 to 600nm.

Optionally, the atomic concentration of carbon in the protective layer,normalized to 100% of carbon, oxygen, and silicon, as determined byX-ray photoelectron spectroscopy (XPS), can be greater than the atomicconcentration of carbon in the atomic formula for the organosiliconprecursor. For example, embodiments are contemplated in which the atomicconcentration of carbon increases by from 1 to 80 atomic percent,alternatively from 10 to 70 atomic percent, alternatively from 20 to 60atomic percent, alternatively from 30 to 50 atomic percent,alternatively from 35 to 45 atomic percent, alternatively from 37 to 41atomic percent.

Optionally, the atomic ratio of carbon to oxygen in the pH protectivecoating or layer can be increased in comparison to the organosiliconprecursor, and/or the atomic ratio of oxygen to silicon can be decreasedin comparison to the organosilicon precursor.

Optionally, the pH protective coating or layer can have an atomicconcentration of silicon, normalized to 100% of carbon, oxygen, andsilicon, as determined by X-ray photoelectron spectroscopy (XPS), lessthan the atomic concentration of silicon in the atomic formula for thefeed gas. For example, embodiments are contemplated in which the atomicconcentration of silicon decreases by from 1 to 80 atomic percent,alternatively by from 10 to 70 atomic percent, alternatively by from 20to 60 atomic percent, alternatively by from 30 to 55 atomic percent,alternatively by from 40 to 50 atomic percent, alternatively by from 42to 46 atomic percent.

As another option, a pH protective coating or layer is contemplated inany embodiment that can be characterized by a sum formula wherein theatomic ratio C:O can be increased and/or the atomic ratio Si:O can bedecreased in comparison to the sum formula of the organosiliconprecursor.

The pH protective coating or layer 286 commonly is located between thebarrier coating or layer 288 and the fluid 218 in the finished article.The pH protective coating or layer 286 is supported by the thermoplasticwall 214.

The pH protective coating or layer 286 optionally is effective to keepthe barrier coating or layer 288 at least substantially undissolved as aresult of attack by the fluid 218 for a period of at least six months.

The pH protective coating or layer can have a density between 1.25 and1.65 g/cm³, alternatively between 1.35 and 1.55 g/cm³, alternativelybetween 1.4 and 1.5 g/cm³, alternatively between 1.4 and 1.5 g/cm³,alternatively between 1.44 and 1.48 g/cm³, as determined by X-rayreflectivity (XRR). Optionally, the organosilicon compound can beoctamethylcyclotetrasiloxane and the pH protective coating or layer canhave a density which can be higher than the density of a pH protectivecoating or layer made from HMDSO as the organosilicon compound under thesame PECVD reaction conditions.

The pH protective coating or layer optionally can prevent or reduce theprecipitation of a compound or component of a composition, in particularcan prevent or reduce insulin precipitation or blood clotting, incomparison to the uncoated surface and/or to a barrier coated surfaceusing HMDSO as precursor.

The pH protective coating or layer optionally can have an RMS surfaceroughness value (measured by AFM) of from about 5 to about 9, optionallyfrom about 6 to about 8, optionally from about 6.4 to about 7.8. TheR_(a) surface roughness value of the pH protective coating or layer,measured by AFM, can be from about 4 to about 6, optionally from about4.6 to about 5.8. The R_(max) surface roughness value of the pHprotective coating or layer, measured by AFM, can be from about 70 toabout 160, optionally from about 84 to about 142, optionally from about90 to about 130.

The interior surface of the pH protective optionally can have a contactangle (with distilled water) of from 90° to 110°, optionally from 80° to120°, optionally from 70° to 130°, as measured by Goniometer Anglemeasurement of a water droplet on the pH protective surface, per ASTMD7334-08 “Standard Practice for Surface Wettability of Coatings,Substrates and Pigments by Advancing Contact Angle Measurement.”

The passivation layer or pH protective coating or layer 286(“passivation layer” and “pH protective coating or layer” are twodifferent names for the same thing) optionally shows an O-Parametermeasured with attenuated total reflection (ATR) Fourier-transforminfrared spectrometry (FTIR) of less than 0.4, measured as:

${O\text{-}{Parameter}} = \frac{{Intensity}\mspace{14mu} {at}\mspace{14mu} 1253\mspace{14mu} {cm}^{- 1}}{{Maximum}\mspace{14mu} {intensity}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {range}\mspace{14mu} 1000\mspace{14mu} {to}{\mspace{11mu} \;}1100\mspace{14mu} {cm}^{- 1}}$

The O-Parameter is defined in U.S. Pat. No. 8,067,070, which claims anO-parameter value of most broadly from 0.4 to 0.9. It can be measuredfrom physical analysis of an FTIR amplitude versus wave number plot tofind the numerator and denominator of the above expression. TheO-Parameter can also be measured from digital wave number versusabsorbance data.

U.S. Pat. No. 8,067,070 asserts that the claimed O-parameter rangeprovides a superior pH protective coating or layer. Surprisingly, it hasbeen found by the present inventors that O-parameters outside the rangesclaimed in U.S. Pat. No. 8,067,070 provide even better results than areobtained in U.S. Pat. No. 8,067,070.

Alternatively in the embodiment of FIGS. 1-5, the O-parameter has avalue of from 0.1 to 0.39, or from 0.15 to 0.37, or from 0.17 to 0.35.

Even another aspect of the invention is a composite material as justdescribed, exemplified in FIGS. 1-5, wherein the passivation layer showsan N-Parameter measured with attenuated total reflection (ATR)Fourier-transform infrared spectrometry (FTIR) of less than 0.7,measured as:

${N\text{-}{Parameter}} = {\frac{{Intensity}\mspace{14mu} {at}\mspace{14mu} 840\mspace{14mu} {cm}^{- 1}}{{Intensity}\mspace{14mu} {at}\mspace{14mu} 799\mspace{14mu} {cm}^{- 1}}.}$

The N-Parameter is also described in U.S. Pat. No. 8,067,070, and ismeasured analogously to the O-Parameter except that intensities at twospecific wave numbers are used—neither of these wave numbers is a range.U.S. Pat. No. 8,067,070 claims a passivation layer with an N-Parameterof 0.7 to 1.6. Again, the present inventors have made better coatingsemploying a pH protective coating or layer 286 having an N-Parameterlower than 0.7, as described above. Alternatively, the N-parameter has avalue of at least 0.3, or from 0.4 to 0.6, or at least 0.53.

The rate of erosion, dissolution, or leaching (different names forrelated concepts) of the pH protective coating or layer 286, if directlycontacted by the fluid 218, is less than the rate of erosion,dissolution, or leaching of the barrier coating or layer 288, ifdirectly contacted by the fluid 218.

The thickness of the pH protective coating or layer is contemplated inany embodiment to be from 50-500 nm, with a preferred range of 100-200nm.

The pH protective coating or layer 286 is effective to isolate the fluid218 from the barrier coating or layer 288, at least for sufficient timeto allow the barrier coating to act as a barrier during the shelf lifeof the pharmaceutical package or other vessel 210.

The inventors have further found that certain pH protective coatings orlayers of SiO_(x)C_(y) or Si(NH)_(x)C_(y) formed from polysiloxaneprecursors, which pH protective coatings or layers have a substantialorganic component, do not erode quickly when exposed to fluids, and infact erode or dissolve more slowly when the fluids have higher pHswithin the range of 5 to 9. For example, at pH 8, the dissolution rateof a pH protective coating or layer made from the precursoroctamethylcyclotetrasiloxane, or OMCTS, is quite slow. These pHprotective coatings or layers of SiO_(x)C_(y) or Si(NH)_(x)C_(y) cantherefore be used to cover a barrier layer of SiO_(x), retaining thebenefits of the barrier layer by protecting it from the fluid in thepharmaceutical package. The protective layer is applied over at least aportion of the SiO_(x) layer to protect the SiO_(x) layer from contentsstored in a vessel, where the contents otherwise would be in contactwith the SiO_(x) layer.

Effective SiO_(x)C_(y) or Si(NH)_(x)C_(y) pH protective coatings orlayers also can be deposited from linear siloxane or linear silazaneprecursors, for example hexamethyldisiloxane (HMDSO) ortetramethyldisiloxane (TMDSO).

Optionally an FTIR absorbance spectrum of the pH protective coating orlayer 286 of any embodiment has a ratio greater than 0.75 between themaximum amplitude of the Si—O—Si symmetrical stretch peak normallylocated between about 1000 and 1040 cm⁻¹, and the maximum amplitude ofthe Si—O—Si asymmetric stretch peak normally located between about 1060and about 1100 cm⁻¹. Alternatively in any embodiment, this ratio can beat least 0.8, or at least 0.9, or at least 1.0, or at least 1.1, or atleast 1.2. Alternatively in any embodiment, this ratio can be at most1.7, or at most 1.6, or at most 1.5, or at most 1.4, or at most 1.3. Anyminimum ratio stated here can be combined with any maximum ratio statedhere, as an alternative embodiment of the invention of FIGS. 1-5.

Optionally, for the pH protective coating or layer 286 in anyembodiment, the silicon dissolution rate by a 50 mM potassium phosphatebuffer diluted in water for injection, adjusted to pH 8 withconcentrated nitric acid, and containing 0.2 wt. % polysorbate-80surfactant, (measured in the absence of the medicament, to avoidchanging the dissolution reagent), at 40° C., is less than 170 ppb/day.(Polysorbate-80 is a common ingredient of pharmaceutical preparations,available for example as Tween®-80 from Uniqema Americas LLC, WilmingtonDel.) Alternatively contemplated dissolution reagents in the testing ofthis paragraph are:

-   -   a potassium phosphate buffer for pH 3;    -   a sodium citrate buffer for pH 6;    -   a potassium phosphate buffer for pH 7;    -   a potassium phosphate buffer for pH 8;    -   a tris buffer for pH 9;    -   a potassium phosphate buffer for pH 12.

Optionally, for the pH protective coating or layer 286 in anyembodiment, the silicon dissolution rate is less than 160 ppb/day, orless than 140 ppb/day, or less than 120 ppb/day, or less than 100ppb/day, or less than 90 ppb/day, or less than 80 ppb/day. Optionally,in any embodiment of FIGS. 13-26 the silicon dissolution rate is morethan 10 ppb/day, or more than 20 ppb/day, or more than 30 ppb/day, ormore than 40 ppb/day, or more than 50 ppb/day, or more than 60 ppb/day.Any minimum rate stated here can be combined with any maximum ratestated here for the pH protective coating or layer 286 in anyembodiment.

Optionally, for the pH protective coating or layer 286 in any embodimentthe total silicon content of the pH protective coating or layer andbarrier coating, upon dissolution into a test composition with a pH of 8from the vessel, is less than 66 ppm, or less than 60 ppm, or less than50 ppm, or less than 40 ppm, or less than 30 ppm, or less than 20 ppm.

pH Protective Coating or Layer Properties of any Embodiment Theory ofOperation

The inventors offer the following theory of operation of the pHprotective coating or layer described here. The invention is not limitedby the accuracy of this theory or to the embodiments predictable by useof this theory.

The dissolution rate of the SiO_(x) barrier layer is believed to bedependent on SiO bonding within the layer. Oxygen bonding sites(silanols) are believed to increase the dissolution rate.

It is believed that the pH protective coating or layer bonds with theSiO_(x) barrier layer to “heal” or passivate the SiO_(x) surface andthus dramatically reduces the dissolution rate. In this hypothesis, thethickness of the pH protective coating or layer is not the primary meansof protection—the primary means is passivation of the SiO_(x) surface.It is contemplated in any embodiment that a pH protective coating orlayer as described in this specification can be improved by increasingthe crosslink density of the pH protective coating or layer.

A pharmaceutical vessel as previously described containing a fluid iscontemplated in any embodiment, in which the fluid comprises a memberselected from the group consisting of:

Inhalation Anesthetics

Aliflurane; Chloroform; Cyclopropane; Desflurane (Suprane); DiethylEther; Enflurane (Ethrane); Ethyl Chloride; Ethylene; Halothane(Fluothane); Isoflurane (Forane, Isoflo); Isopropenyl vinyl ether;Methoxyflurane; methoxyflurane; Methoxypropane; Nitrous Oxide;Roflurane; Sevoflurane (Sevorane, Ultane, Sevoflo); Teflurane;Trichloroethylene; Vinyl Ether; Xenon

Injectable Drugs

Ablavar (Gadofosveset Trisodium Injection); Abarelix Depot;Abobotulinumtoxin A Injection (Dysport); ABT-263; ABT-869; ABX-EFG;Accretropin (Somatropin Injection); Acetadote (AcetylcysteineInjection); Acetazolamide Injection (Acetazolamide Injection);Acetylcysteine Injection (Acetadote); Actemra (Tocilizumab Injection);Acthrel (Corticorelin Ovine Triflutate for Injection); Actummune;Activase; Acyclovir for Injection (Zovirax Injection); Adacel;Adalimumab; Adenoscan (Adenosine Injection); Adenosine Injection(Adenoscan); Adrenaclick; AdreView (lobenguane I 123 Injection forIntravenous Use); Afluria; Ak-Fluor (Fluorescein Injection); Aldurazyme(Laronidase); Alglucerase Injection (Ceredase); Alkeran Injection(Melphalan Hcl Injection); Allopurinol Sodium for Injection (Aloprim);Aloprim (Allopurinol Sodium for Injection); Alprostadil; Alsuma(Sumatriptan Injection); ALTU-238; Amino Acid Injections; Aminosyn;Apidra; Apremilast; Alprostadil Dual Chamber System for Injection(Caverject Impulse); AMG 009; AMG 076; AMG 102; AMG 108; AMG 114; AMG162; AMG 220; AMG 221; AMG 222; AMG 223; AMG 317; AMG 379; AMG 386; AMG403; AMG 477; AMG 479; AMG 517; AMG 531; AMG 557; AMG 623; AMG 655; AMG706; AMG 714; AMG 745; AMG 785; AMG 811; AMG 827; AMG 837; AMG 853; AMG951; Amiodarone HCl Injection (Amiodarone HCl Injection); AmobarbitalSodium Injection (Amytal Sodium); Amytal Sodium (Amobarbital SodiumInjection); Anakinra; Anti-Abeta; Anti-Beta7; Anti-Beta20; Anti-CD4;Anti-CD20; Anti-CD40; Anti-IFNalpha; Anti-IL13; Anti-OX40L; Anti-oxLDS;Anti-NGF; Anti-NRP1; Arixtra; Amphadase (Hyaluronidase Inj); Ammonul(Sodium Phenylacetate and Sodium Benzoate Injection); Anaprox; AnzemetInjection (Dolasetron Mesylate Injection); Apidra (Insulin Glulisine[rDNA origin] Inj); Apomab; Aranesp (darbepoetin alfa); Argatroban(Argatroban Injection); Arginine Hydrochloride Injection (R-Gene 10);Aristocort; Aristospan; Arsenic Trioxide Injection (Trisenox); ArticaneHCl and Epinephrine Injection (Septocaine); Arzerra (OfatumumabInjection); Asclera (Polidocanol Injection); Ataluren; Ataluren-DMD;Atenolol Inj (Tenormin I.V. Injection); Atracurium Besylate Injection(Atracurium Besylate Injection); Avastin; Azactam Injection (AztreonamInjection); Azithromycin (Zithromax Injection); Aztreonam Injection(Azactam Injection); Baclofen Injection (Lioresal Intrathecal);Bacteriostatic Water (Bacteriostatic Water for Injection); BaclofenInjection (Lioresal Intrathecal); Bal in Oil Ampules (DimercarprolInjection); BayHepB; BayTet; Benadryl; Bendamustine HydrochlorideInjection (Treanda); Benztropine Mesylate Injection (Cogentin);Betamethasone Injectable Suspension (Celestone Soluspan); Bexxar;Bicillin C-R 900/300 (Penicillin G Benzathine and Penicillin G ProcaineInjection); Blenoxane (Bleomycin Sulfate Injection); Bleomycin SulfateInjection (Blenoxane); Boniva Injection (Ibandronate Sodium Injection);Botox Cosmetic (OnabotulinumtoxinA for Injection); BR3-FC; Bravelle(Urofollitropin Injection); Bretylium (Bretylium Tosylate Injection);Brevital Sodium (Methohexital Sodium for Injection); Brethine;Briobacept; BTT-1023; Bupivacaine HCl; Byetta; Ca-DTPA (PentetateCalcium Trisodium Inj); Cabazitaxel Injection (Jevtana); CaffeineAlkaloid (Caffeine and Sodium Benzoate Injection); Calcijex Injection(Calcitrol); Calcitrol (Calcijex Injection); Calcium Chloride (CalciumChloride Injection 10%); Calcium Disodium Versenate (Edetate CalciumDisodium Injection); Campath (Altemtuzumab); Camptosar Injection(Irinotecan Hydrochloride); Canakinumab Injection (Ilaris); CapastatSulfate (Capreomycin for Injection); Capreomycin for Injection (CapastatSulfate); Cardiolite (Prep kit for Technetium Tc99 Sestamibi forInjection); Carticel; Cathflo; Cefazolin and Dextrose for Injection(Cefazolin Injection); Cefepime Hydrochloride; Cefotaxime; Ceftriaxone;Cerezyme; Carnitor Injection; Caverject; Celestone Soluspan; Celsior;Cerebyx (Fosphenytoin Sodium Injection); Ceredase (AlgluceraseInjection); Ceretec (Technetium Tc99m Exametazime Injection);Certolizumab; CF-101; Chloramphenicol Sodium Succinate (ChloramphenicolSodium Succinate Injection); Chloramphenicol Sodium Succinate Injection(Chloramphenicol Sodium Succinate); Cholestagel (Colesevelam HCL);Choriogonadotropin Alfa Injection (Ovidrel); Cimzia; Cisplatin(Cisplatin Injection); Clolar (Clofarabine Injection); ClomiphineCitrate; Clonidine Injection (Duraclon); Cogentin (Benztropine MesylateInjection); Colistimethate Injection (Coly-Mycin M); Coly-Mycin M(Colistimethate Injection); Compath; Conivaptan Hcl Injection(Vaprisol); Conjugated Estrogens for Injection (Premarin Injection);Copaxone; Corticorelin Ovine Triflutate for Injection (Acthrel); Corvert(Ibutilide Fumarate Injection); Cubicin (Daptomycin Injection); CF-101;Cyanokit (Hydroxocobalamin for Injection); Cytarabine Liposome Injection(DepoCyt); Cyanocobalamin; Cytovene (ganciclovir); D.H.E. 45;Dacetuzumab; Dacogen (Decitabine Injection); Dalteparin; Dantrium IV(Dantrolene Sodium for Injection); Dantrolene Sodium for Injection(Dantrium IV); Daptomycin Injection (Cubicin); Darbepoietin Alfa; DDAVPInjection (Desmopressin Acetate Injection); Decavax; DecitabineInjection (Dacogen); Dehydrated Alcohol (Dehydrated Alcohol Injection);Denosumab Injection (Prolia); Delatestryl; Delestrogen; DelteparinSodium; Depacon (Valproate Sodium Injection); Depo Medrol(Methylprednisolone Acetate Injectable Suspension); DepoCyt (CytarabineLiposome Injection); DepoDur (Morphine Sulfate XR Liposome Injection);Desmopressin Acetate Injection (DDAVP Injection); Depo-Estradiol;Depo-Provera 104 mg/ml; Depo-Provera 150 mg/ml; Depo-Testosterone;Dexrazoxane for Injection, Intravenous Infusion Only (Totect);Dextrose/Electrolytes; Dextrose and Sodium Chloride Inj (Dextrose 5% in0.9% Sodium Chloride); Dextrose; Diazepam Injection (DiazepamInjection); Digoxin Injection (Lanoxin Injection); Dilaudid-HP(Hydromorphone Hydrochloride Injection); Dimercarprol Injection (Bal inOil Ampules); Diphenhydramine Injection (Benadryl Injection);Dipyridamole Injection (Dipyridamole Injection); DMOAD; Docetaxel forInjection (Taxotere); Dolasetron Mesylate Injection (Anzemet Injection);Doribax (Doripenem for Injection); Doripenem for Injection (Doribax);Doxercalciferol Injection (Hectorol Injection); Doxil (Doxorubicin HclLiposome Injection); Doxorubicin Hcl Liposome Injection (Doxil);Duraclon (Clonidine Injection); Duramorph (Morphine Injection); Dysport(Abobotulinumtoxin A Injection); Ecallantide Injection (Kalbitor);EC-Naprosyn (naproxen); Edetate Calcium Disodium Injection (CalciumDisodium Versenate); Edex (Alprostadil for Injection); Engerix;Edrophonium Injection (Enlon); Eliglustat Tartate; Eloxatin (OxaliplatinInjection); Emend Injection (Fosaprepitant Dimeglumine Injection);Enalaprilat Injection (Enalaprilat Injection); Enlon (EdrophoniumInjection); Enoxaparin Sodium Injection (Lovenox); Eovist (GadoxetateDisodium Injection); Enbrel (etanercept); Enoxaparin; Epicel;Epinepherine; Epipen; Epipen Jr.; Epratuzumab; Erbitux; ErtapenemInjection (Invanz); Erythropoieten; Essential Amino Acid Injection(Nephramine); Estradiol Cypionate; Estradiol Valerate; Etanercept;Exenatide Injection (Byetta); Evlotra; Fabrazyme (Adalsidase beta);Famotidine Injection; FDG (Fludeoxyglucose F 18 Injection); Feraheme(Ferumoxytol Injection); Feridex I.V. (Ferumoxides Injectable Solution);Fertinex; Ferumoxides Injectable Solution (Feridex I.V.); FerumoxytolInjection (Feraheme); Flagyl Injection (Metronidazole Injection);Fluarix; Fludara (Fludarabine Phosphate); Fludeoxyglucose F 18 Injection(FDG); Fluorescein Injection (Ak-Fluor); Follistim AQ Cartridge(Follitropin Beta Injection); Follitropin Alfa Injection (Gonal-f RFF);Follitropin Beta Injection (Follistim AQ Cartridge); Folotyn(Pralatrexate Solution for Intravenous Injection); Fondaparinux; Forteo(Teriparatide (rDNA origin) Injection); Fostamatinib; FosaprepitantDimeglumine Injection (Emend Injection); Foscarnet Sodium Injection(Foscavir); Foscavir (Foscarnet Sodium Injection); Fosphenytoin SodiumInjection (Cerebyx); Fospropofol Disodium Injection (Lusedra); Fragmin;Fuzeon (enfuvirtide); GA101; Gadobenate Dimeglumine Injection(Multihance); Gadofosveset Trisodium Injection (Ablavar); GadoteridolInjection Solution (ProHance); Gadoversetamide Injection (OptiMARK);Gadoxetate Disodium Injection (Eovist); Ganirelix (Ganirelix AcetateInjection); Gardasil; GC1008; GDFD; Gemtuzumab Ozogamicin for Injection(Mylotarg); Genotropin; Gentamicin Injection; GENZ-112638; GolimumabInjection (Simponi Injection); Gonal-f RFF (Follitropin Alfa Injection);Granisetron Hydrochloride (Kytril Injection); Gentamicin Sulfate;Glatiramer Acetate; Glucagen; Glucagon; HAE1; Haldol (HaloperidolInjection); Havrix; Hectorol Injection (Doxercalciferol Injection);Hedgehog Pathway Inhibitor; Heparin; Herceptin; hG-CSF; Humalog; HumanGrowth Hormone; Humatrope; HuMax; Humegon; Humira; Humulin; IbandronateSodium Injection (Boniva Injection); Ibuprofen Lysine Injection(NeoProfen); Ibutilide Fumarate Injection (Corvert); Idamycin PFS(Idarubicin Hydrochloride Injection); Idarubicin Hydrochloride Injection(Idamycin PFS); Ilaris (Canakinumab Injection); Imipenem and Cilastatinfor Injection (Primaxin I.V.); Imitrex; Incobotulinumtoxin A forInjection (Xeomin); Increlex (Mecasermin [rDNA origin] Injection);Indocin IV (Indomethacin Inj); Indomethacin Inj (Indocin IV); Infanrix;Innohep; Insulin; Insulin Aspart [rDNA origin] Inj (NovoLog); InsulinGlargine [rDNA origin] Injection (Lantus); Insulin Glulisine [rDNAorigin] Inj (Apidra); Interferon alfa-2b, Recombinant for Injection(Intron A); Intron A (Interferon alfa-2b, Recombinant for Injection);Invanz (Ertapenem Injection); Invega Sustenna (Paliperidone PalmitateExtended-Release Injectable Suspension); Invirase (saquinavir mesylate);lobenguane I 123 Injection for Intravenous Use (AdreView); lopromideInjection (Ultravist); loversol Injection (Optiray Injection); Iplex(Mecasermin Rinfabate [rDNA origin] Injection); Iprivask; IrinotecanHydrochloride (Camptosar Injection); Iron Sucrose Injection (Venofer);Istodax (Romidepsin for Injection); Itraconazole Injection (SporanoxInjection); Jevtana (Cabazitaxel Injection); Jonexa; Kalbitor(Ecallantide Injection); KCL in D5NS (Potassium Chloride in 5% Dextroseand Sodium Chloride Injection); KCL in D5W; KCL in NS; Kenalog 10Injection (Triamcinolone Acetonide Injectable Suspension); Kepivance(Palifermin); Keppra Injection (Levetiracetam); Keratinocyte; KFG;Kinase Inhibitor; Kineret (Anakinra); Kinlytic (Urokinase Injection);Kinrix; Klonopin (clonazepam); Kytril Injection (GranisetronHydrochloride); lacosamide Tablet and Injection (Vimpat); LactatedRinger's; Lanoxin Injection (Digoxin Injection); Lansoprazole forInjection (Prevacid I.V.); Lantus; Leucovorin Calcium (LeucovorinCalcium Injection); Lente (L); Leptin; Levemir; Leukine Sargramostim;Leuprolide Acetate; Levothyroxine; Levetiracetam (Keppra Injection);Lovenox; Levocarnitine Injection (Carnitor Injection); Lexiscan(Regadenoson Injection); Lioresal Intrathecal (Baclofen Injection);Liraglutide [rDNA] Injection (Victoza); Lovenox (Enoxaparin SodiumInjection); Lucentis (Ranibizumab Injection); Lumizyme; Lupron(Leuprolide Acetate Injection); Lusedra (Fospropofol DisodiumInjection); Maci; Magnesium Sulfate (Magnesium Sulfate Injection);Mannitol Injection (Mannitol IV); Marcaine (Bupivacaine Hydrochlorideand Epinephrine Injection); Maxipime (Cefepime Hydrochloride forInjection); MDP Multidose Kit of Technetium Injection (Technetium Tc99mMedronate Injection); Mecasermin [rDNA origin] Injection (Increlex);Mecasermin Rinfabate [rDNA origin] Injection (Iplex); Melphalan HclInjection (Alkeran Injection); Methotrexate; Menactra; Menopur(Menotropins Injection); Menotropins for Injection (Repronex);Methohexital Sodium for Injection (Brevital Sodium); MethyldopateHydrochloride Injection, Solution (Methyldopate Hcl); Methylene Blue(Methylene Blue Injection); Methylprednisolone Acetate InjectableSuspension (Depo Medrol); MetMab; Metoclopramide Injection (ReglanInjection); Metrodin (Urofollitropin for Injection); MetronidazoleInjection (Flagyl Injection); Miacalcin; Midazolam (MidazolamInjection); Mimpara (Cinacalet); Minocin Injection (Minocycline Inj);Minocycline Inj (Minocin Injection); Mipomersen; Mitoxantrone forInjection Concentrate (Novantrone); Morphine Injection (Duramorph);Morphine Sulfate XR Liposome Injection (DepoDur); Morrhuate Sodium(Morrhuate Sodium Injection); Motesanib; Mozobil (Plerixafor Injection);Multihance (Gadobenate Dimeglumine Injection); Multiple Electrolytes andDextrose Injection; Multiple Electrolytes Injection; Mylotarg(Gemtuzumab Ozogamicin for Injection); Myozyme (Alglucosidase alfa);Nafcillin Injection (Nafcillin Sodium); Nafcillin Sodium (NafcillinInjection); Naltrexone XR Inj (Vivitrol); Naprosyn (naproxen); NeoProfen(Ibuprofen Lysine Injection); Nandrol Decanoate; NeostigmineMethylsulfate (Neostigmine Methylsulfate Injection); NEO-GAA; NeoTect(Technetium Tc 99m Depreotide Injection); Nephramine (Essential AminoAcid Injection); Neulasta (pegfilgrastim); Neupogen (Filgrastim);Novolin; Novolog; NeoRecormon; Neutrexin (Trimetrexate Glucuronate Inj);NPH (N); Nexterone (Amiodarone HCl Injection); Norditropin (SomatropinInjection); Normal Saline (Sodium Chloride Injection); Novantrone(Mitoxantrone for Injection Concentrate); Novolin 70/30 Innolet (70%NPH, Human Insulin Isophane Suspension and 30% Regular, Human InsulinInjection); NovoLog (Insulin Aspart [rDNA origin] Inj); Nplate(romiplostim); Nutropin (Somatropin (rDNA origin) for Inj); Nutropin AQ;Nutropin Depot (Somatropin (rDNA origin) for Inj); Octreotide AcetateInjection (Sandostatin LAR); Ocrelizumab; Ofatumumab Injection(Arzerra); Olanzapine Extended Release Injectable Suspension (ZyprexaRelprevv); Omnitarg; Omnitrope (Somatropin [rDNA origin] Injection);Ondansetron Hydrochloride Injection (Zofran Injection); OptiMARK(Gadoversetamide Injection); Optiray Injection (loversol Injection);Orencia; Osmitrol Injection in Aviva (Mannitol Injection in AvivaPlastic Vessel); Osmitrol Injection in Viaflex (Mannitol Injection inViaflex Plastic Vessel); Osteoprotegrin; Ovidrel (ChoriogonadotropinAlfa Injection); Oxacillin (Oxacillin for Injection); OxaliplatinInjection (Eloxatin); Oxytocin Injection (Pitocin); PaliperidonePalmitate Extended-Release Injectable Suspension (Invega Sustenna);Pamidronate Disodium Injection (Pamidronate Disodium Injection);Panitumumab Injection for Intravenous Use (Vectibix); PapaverineHydrochloride Injection (Papaverine Injection); Papaverine Injection(Papaverine Hydrochloride Injection); Parathyroid Hormone; ParicalcitolInjection Fliptop Vial (Zemplar Injection); PARP Inhibitor; Pediarix;PEGlntron; Peginterferon; Pegfilgrastim; Penicillin G Benzathine andPenicillin G Procaine; Pentetate Calcium Trisodium Inj (Ca-DTPA);Pentetate Zinc Trisodium Injection (Zn-DTPA); Pepcid Injection(Famotidine Injection); Pergonal; Pertuzumab; Phentolamine Mesylate(Phentolamine Mesylate for Injection); Physostigmine Salicylate(Physostigmine Salicylate (injection)); Physostigmine Salicylate(injection) (Physostigmine Salicylate); Piperacillin and TazobactamInjection (Zosyn); Pitocin (Oxytocin Injection); Plasma-Lyte 148(Multiple Electrolytes Inj); Plasma-Lyte 56 and Dextrose (MultipleElectrolytes and Dextrose Injection in Viaflex Plastic Vessel);PlasmaLyte; Plerixafor Injection (Mozobil); Polidocanol Injection(Asclera); Potassium Chloride; Pralatrexate Solution for IntravenousInjection (Folotyn); Pramlintide Acetate Injection (Symlin); PremarinInjection (Conjugated Estrogens for Injection); Prep kit for TechnetiumTc99 Sestamibi for Injection (Cardiolite); Prevacid I.V. (Lansoprazolefor Injection); Primaxin I.V. (Imipenem and Cilastatin for Injection);Prochymal; Procrit; Progesterone; ProHance (Gadoteridol InjectionSolution); Prolia (Denosumab Injection); Promethazine HCl Injection(Promethazine Hydrochloride Injection); Propranolol HydrochlorideInjection (Propranolol Hydrochloride Injection); Quinidine GluconateInjection (Quinidine Injection); Quinidine Injection (QuinidineGluconate Injection); R-Gene 10 (Arginine Hydrochloride Injection);Ranibizumab Injection (Lucentis); Ranitidine Hydrochloride Injection(Zantac Injection); Raptiva; Reclast (Zoledronic Acid Injection);Recombivarix HB; Regadenoson Injection (Lexiscan); Reglan Injection(Metoclopramide Injection); Remicade; Renagel; Renvela (SevelamerCarbonate); Repronex (Menotropins for Injection); Retrovir IV(Zidovudine Injection); rhApo2L/TRAIL; Ringer's and 5% DextroseInjection (Ringers in Dextrose); Ringer's Injection (Ringers Injection);Rituxan; Rituximab; Rocephin (ceftriaxone); Rocuronium Bromide Injection(Zemuron); Roferon-A (interferon alfa-2a); Romazicon (flumazenil);Romidepsin for Injection (Istodax); Saizen (Somatropin Injection);Sandostatin LAR (Octreotide Acetate Injection); Sclerostin Ab; Sensipar(cinacalcet); Sensorcaine (Bupivacaine HCl Injections); Septocaine(Articane HCl and Epinephrine Injection); Serostim LQ (Somatropin (rDNAorigin) Injection); Simponi Injection (Golimumab Injection); SodiumAcetate (Sodium Acetate Injection); Sodium Bicarbonate (SodiumBicarbonate 5% Injection); Sodium Lactate (Sodium Lactate Injection inAVIVA); Sodium Phenylacetate and Sodium Benzoate Injection (Ammonul);Somatropin (rDNA origin) for Inj (Nutropin); Sporanox Injection(Itraconazole Injection); Stelara Injection (Ustekinumab); Stemgen;Sufenta (Sufentanil Citrate Injection); Sufentanil Citrate Injection(Sufenta); Sumavel; Sumatriptan Injection (Alsuma); Symlin; Symlin Pen;Systemic Hedgehog Antagonist; Synvisc-One (Hylan G-F 20 SingleIntra-articular Injection); Tarceva; Taxotere (Docetaxel for Injection);Technetium Tc 99m; Telavancin for Injection (Vibativ); TemsirolimusInjection (Torisel); Tenormin I.V. Injection (Atenolol Inj);Teriparatide (rDNA origin) Injection (Forteo); Testosterone Cypionate;Testosterone Enanthate; Testosterone Propionate; Tev-Tropin (Somatropin,rDNA Origin, for Injection); tgAAC94; Thallous Chloride; Theophylline;Thiotepa (Thiotepa Injection); Thymoglobulin (Anti-Thymocyte Globulin(Rabbit); Thyrogen (Thyrotropin Alfa for Injection); TicarcillinDisodium and Clavulanate Potassium Galaxy (Timentin Injection); TiganInjection (Trimethobenzamide Hydrochloride Injectable); TimentinInjection (Ticarcillin Disodium and Clavulanate Potassium Galaxy);TNKase; Tobramycin Injection (Tobramycin Injection); TocilizumabInjection (Actemra); Torisel (Temsirolimus Injection); Totect(Dexrazoxane for Injection, Intravenous Infusion Only); Trastuzumab-DM1;Travasol (Amino Acids (Injection)); Treanda (Bendamustine HydrochlorideInjection); Trelstar (Triptorelin Pamoate for Injectable Suspension);Triamcinolone Acetonide; Triamcinolone Diacetate; TriamcinoloneHexacetonide Injectable Suspension (Aristospan Injection 20 mg);Triesence (Triamcinolone Acetonide Injectable Suspension);Trimethobenzamide Hydrochloride Injectable (Tigan Injection);Trimetrexate Glucuronate Inj (Neutrexin); Triptorelin Pamoate forInjectable Suspension (Trelstar); Twinject; Trivaris (TriamcinoloneAcetonide Injectable Suspension); Trisenox (Arsenic Trioxide Injection);Twinrix; Typhoid Vi; Ultravist (lopromide Injection); Urofollitropin forInjection (Metrodin); Urokinase Injection (Kinlytic); Ustekinumab(Stelara Injection); Ultralente (U); Valium (diazepam); Valproate SodiumInjection (Depacon); Valtropin (Somatropin Injection); VancomycinHydrochloride (Vancomycin Hydrochloride Injection); VancomycinHydrochloride Injection (Vancomycin Hydrochloride); Vaprisol (ConivaptanHcl Injection); VAQTA; Vasovist (Gadofosveset Trisodium Injection forIntravenous Use); Vectibix (Panitumumab Injection for Intravenous Use);Venofer (Iron Sucrose Injection); Verteporfin Inj (Visudyne); Vibativ(Telavancin for Injection); Victoza (Liraglutide [rDNA] Injection);Vimpat (lacosamide Tablet and Injection); Vinblastine Sulfate(Vinblastine Sulfate Injection); Vincasar PFS (Vincristine SulfateInjection); Victoza; Vincristine Sulfate (Vincristine SulfateInjection); Visudyne (Verteporfin Inj); Vitamin B-12; Vivitrol(Naltrexone XR Inj); Voluven (Hydroxyethyl Starch in Sodium ChlorideInjection); Xeloda; Xenical (orlistat); Xeomin (Incobotulinumtoxin A forInjection); Xolair; Zantac Injection (Ranitidine HydrochlorideInjection); Zemplar Injection (Paricalcitol Injection Fliptop Vial);Zemuron (Rocuronium Bromide Injection); Zenapax (daclizumab); Zevalin;Zidovudine Injection (Retrovir IV); Zithromax Injection (Azithromycin);Zn-DTPA (Pentetate Zinc Trisodium Injection); Zofran Injection(Ondansetron Hydrochloride Injection); Zingo; Zoledronic Acid for Inj(Zometa); Zoledronic Acid Injection (Reclast); Zometa (Zoledronic Acidfor Inj); Zosyn (Piperacillin and Tazobactam Injection); ZyprexaRelprevv (Olanzapine Extended Release Injectable Suspension)

Liquid Drugs (Non-Injectable)

Abilify; AccuNeb (Albuterol Sulfate Inhalation Solution); Actidose Aqua(Activated Charcoal Suspension); Activated Charcoal Suspension (ActidoseAqua); Advair; Agenerase Oral Solution (Amprenavir Oral Solution); Akten(Lidocaine Hydrochloride Ophthalmic Gel); Alamast (Pemirolast PotassiumOphthalmic Solution); Albumin (Human) 5% Solution (Buminate 5%);Albuterol Sulfate Inhalation Solution; Alinia; Alocril; Alphagan; Alrex;Alvesco; Amprenavir Oral Solution; Analpram-HC; Arformoterol TartrateInhalation Solution (Brovana); Aristospan Injection 20 mg (TriamcinoloneHexacetonide Injectable Suspension); Asacol; Asmanex; Astepro; Astepro(Azelastine Hydrochloride Nasal Spray); Atrovent Nasal Spray(Ipratropium Bromide Nasal Spray); Atrovent Nasal Spray 0.06; AugmentinES-600; Azasite (Azithromycin Ophthalmic Solution); Azelaic Acid(Finacea Gel); Azelastine Hydrochloride Nasal Spray (Astepro); Azelex(Azelaic Acid Cream); Azopt (Brinzolamide Ophthalmic Suspension);Bacteriostatic Saline; Balanced Salt; Bepotastine; Bactroban Nasal;Bactroban; Beclovent; Benzac W; Betimol; Betoptic S; Bepreve;Bimatoprost Ophthalmic Solution; Bleph 10 (Sulfacetamide SodiumOphthalmic Solution 10%); Brinzolamide Ophthalmic Suspension (Azopt);Bromfenac Ophthalmic Solution (Xibrom); Bromhist; Brovana (ArformoterolTartrate Inhalation Solution); Budesonide Inhalation Suspension(Pulmicort Respules); Cambia (Diclofenac Potassium for Oral Solution);Capex; Carac; Carboxine-PSE; Carnitor; Cayston (Aztreonam for InhalationSolution); Cellcept; Centany; Cerumenex; Ciloxan Ophthalmic Solution(Ciprofloxacin HCL Ophthalmic Solution); Ciprodex; Ciprofloxacin HCLOphthalmic Solution (Ciloxan Ophthalmic Solution); Clemastine FumarateSyrup (Clemastine Fumarate Syrup); CoLyte (PEG Electrolytes Solution);Combiven; Comtan; Condylox; Cordran; Cortisporin Ophthalmic Suspension;Cortisporin Otic Suspension; Cromolyn Sodium Inhalation Solution (IntalNebulizer Solution); Cromolyn Sodium Ophthalmic Solution (Opticrom);Crystalline Amino Acid Solution with Electrolytes (AminosynElectrolytes); Cutivate; Cuvposa (Glycopyrrolate Oral Solution);Cyanocobalamin (CaloMist Nasal Spray); Cyclosporine Oral Solution(Gengraf Oral Solution); Cyclogyl; Cysview (HexaminolevulinateHydrochloride Intravesical Solution); DermOtic Oil (FluocinoloneAcetonide Oil Ear Drops); Desmopressin Acetate Nasal Spray; DDAVP;Derma-Smoothe/FS; Dexamethasone Intensol; Dianeal Low Calcium; DianealPD; Diclofenac Potassium for Oral Solution (Cambia); DidanosinePediatric Powder for Oral Solution (Videx); Differin; Dilantin 125(Phenytoin Oral Suspension); Ditropan; Dorzolamide HydrochlorideOphthalmic Solution (Trusopt); Dorzolamide Hydrochloride-Timolol MaleateOphthalmic Solution (Cosopt); Dovonex Scalp (Calcipotriene Solution);Doxycycline Calcium Oral Suspension (Vibramycin Oral); Efudex; Elaprase(Idursulfase Solution); Elestat (Epinastine HCl Ophthalmic Solution);Elocon; Epinastine HCl Ophthalmic Solution (Elestat); Epivir HBV; Epogen(Epoetin alfa); Erythromycin Topical Solution 1.5% (Staticin); Ethiodol(Ethiodized Oil); Ethosuximide Oral Solution (Zarontin Oral Solution);Eurax; Extraneal (Icodextrin Peritoneal Dialysis Solution); Felbatol;Feridex I.V. (Ferumoxides Injectable Solution); Flovent; Floxin Otic(Ofloxacin Otic Solution); Flo-Pred (Prednisolone Acetate OralSuspension); Fluoroplex; Flunisolide Nasal Solution (Flunisolide NasalSpray 0.025%); Fluorometholone Ophthalmic Suspension (FML); FlurbiprofenSodium Ophthalmic Solution (Ocufen); FML; Foradil; Formoterol FumarateInhalation Solution (Perforomist); Fosamax; Furadantin (NitrofurantoinOral Suspension); Furoxone; Gammagard Liquid (Immune GlobulinIntravenous (Human) 10%); Gantrisin (Acetyl Sulfisoxazole PediatricSuspension); Gatifloxacin Ophthalmic Solution (Zymar); Gengraf OralSolution (Cyclosporine Oral Solution); Glycopyrrolate Oral Solution(Cuvposa); Halcinonide Topical Solution (Halog Solution); Halog Solution(Halcinonide Topical Solution); HEP-LOCK U/P (Preservative-Free HeparinLock Flush Solution); Heparin Lock Flush Solution (Hepflush 10);Hexaminolevulinate Hydrochloride Intravesical Solution (Cysview);Hydrocodone Bitartrate and Acetaminophen Oral Solution (Lortab Elixir);Hydroquinone 3% Topical Solution (Melquin-3 Topical Solution); IAPAntagonist; Isopto; Ipratropium Bromide Nasal Spray (Atrovent NasalSpray); Itraconazole Oral Solution (Sporanox Oral Solution); KetorolacTromethamine Ophthalmic Solution (Acular LS); Kaletra; Lanoxin; Lexiva;Leuprolide Acetate for Depot Suspension (Lupron Depot 11.25 mg);Levobetaxolol Hydrochloride Ophthalmic Suspension (Betaxon);Levocarnitine Tablets, Oral Solution, Sugar-Free (Carnitor);Levofloxacin Ophthalmic Solution 0.5% (Quixin); Lidocaine HCl SterileSolution (Xylocaine MPF Sterile Solution); Lok Pak (Heparin Lock FlushSolution); Lorazepam Intensol; Lortab Elixir (Hydrocodone Bitartrate andAcetaminophen Oral Solution); Lotemax (Loteprednol Etabonate OphthalmicSuspension); Loteprednol Etabonate Ophthalmic Suspension (Alrex); LowCalcium Peritoneal Dialysis Solutions (Dianeal Low Calcium); Lumigan(Bimatoprost Ophthalmic Solution 0.03% for Glaucoma); Lupron Depot 11.25mg (Leuprolide Acetate for Depot Suspension); Megestrol Acetate OralSuspension (Megestrol Acetate Oral Suspension); MEK Inhibitor; Mepron;Mesnex; Mestinon; Mesalamine Rectal Suspension Enema (Rowasa); Melquin-3Topical Solution (Hydroquinone 3% Topical Solution); MetMab;Methyldopate Hcl (Methyldopate Hydrochloride Injection, Solution);Methylin Oral Solution (Methylphenidate HCl Oral Solution 5 mg/5 mL and10 mg/5 mL); Methylprednisolone Acetate Injectable Suspension (DepoMedrol); Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL(Methylin Oral Solution); Methylprednisolone sodium succinate (SoluMedrol); Metipranolol Ophthalmic Solution (Optipranolol); Migranal;Miochol-E (Acetylcholine Chloride Intraocular Solution); Micro-K forLiquid Suspension (Potassium Chloride Extended Release Formulation forLiquid Suspension); Minocin (Minocycline Hydrochloride Oral Suspension);Nasacort; Neomycin and Polymyxin B Sulfates and Hydrocortisone;Nepafenac Ophthalmic Suspension (Nevanac); Nevanac (Nepafenac OphthalmicSuspension); Nitrofurantoin Oral Suspension (Furadantin); Noxafil(Posaconazole Oral Suspension); Nystatin (oral) (Nystatin OralSuspension); Nystatin Oral Suspension (Nystatin (oral)); Ocufen(Flurbiprofen Sodium Ophthalmic Solution); Ofloxacin Ophthalmic Solution(Ofloxacin Ophthalmic Solution); Ofloxacin Otic Solution (Floxin Otic);Olopatadine Hydrochloride Ophthalmic Solution (Pataday); Opticrom(Cromolyn Sodium Ophthalmic Solution); Optipranolol (MetipranololOphthalmic Solution); Patanol; Pediapred; PerioGard; Phenytoin OralSuspension (Dilantin 125); Phisohex; Posaconazole Oral Suspension(Noxafil); Potassium Chloride Extended Release Formulation for LiquidSuspension (Micro-K for Liquid Suspension); Pataday (OlopatadineHydrochloride Ophthalmic Solution); Patanase Nasal Spray (OlopatadineHydrochloride Nasal Spray); PEG Electrolytes Solution (CoLyte);Pemirolast Potassium Ophthalmic Solution (Alamast); Penlac (CiclopiroxTopical Solution); PENNSAID (Diclofenac Sodium Topical Solution);Perforomist (Formoterol Fumarate Inhalation Solution); PeritonealDialysis Solution; Phenylephrine Hydrochloride Ophthalmic Solution(Neo-Synephrine); Phospholine Iodide (Echothiophate Iodide forOphthalmic Solution); Podofilox (Podofilox Topical Solution); Pred Forte(Prednisolone Acetate Ophthalmic Suspension); Pralatrexate Solution forIntravenous Injection (Folotyn); Pred Mild; Prednisone Intensol;Prednisolone Acetate Ophthalmic Suspension (Pred Forte); Prevacid;PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution);ProAir; Proglycem; ProHance (Gadoteridol Injection Solution);Proparacaine Hydrochloride Ophthalmic Solution (Alcaine); Propine;Pulmicort; Pulmozyme; Quixin (Levofloxacin Ophthalmic Solution 0.5%);QVAR; Rapamune; Rebetol; Relacon-HC; Rotarix (Rotavirus Vaccine, Live,Oral Suspension); Rotavirus Vaccine, Live, Oral Suspension (Rotarix);Rowasa (Mesalamine Rectal Suspension Enema); Sabril (Vigabatrin OralSolution); Sacrosidase Oral Solution (Sucraid); Sandimmune; Sepra;Serevent Diskus; Solu Cortef (Hydrocortisone Sodium Succinate); SoluMedrol (Methylprednisolone sodium succinate); Spiriva; Sporanox OralSolution (Itraconazole Oral Solution); Staticin (Erythromycin TopicalSolution 1.5%); Stalevo; Starlix; Sterile HemofiltrationHemodiafiltration Solution (PrismaSol Solution); Stimate; Sucralfate(Carafate Suspension); Sulfacetamide Sodium Ophthalmic Solution 10%(Bleph 10); Synarel Nasal Solution (Nafarelin Acetate Nasal Solution forEndometriosis); Taclonex Scalp (Calcipotriene and BetamethasoneDipropionate Topical Suspension); Tamiflu; Tobi; TobraDex; Tobradex ST(Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05%);Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05% (Tobradex ST);Timolol; Timoptic; Travatan Z; Treprostinil Inhalation Solution(Tyvaso); Trusopt (Dorzolamide Hydrochloride Ophthalmic Solution);Tyvaso (Treprostinil Inhalation Solution); Ventolin; Vfend; VibramycinOral (Doxycycline Calcium Oral Suspension); Videx (Didanosine PediatricPowder for Oral Solution); Vigabatrin Oral Solution (Sabril); Viokase;Viracept; Viramune; Vitamin K1 (Fluid Colloidal Solution of Vitamin K1);Voltaren Ophthalmic (Diclofenac Sodium Ophthalmic Solution); ZarontinOral Solution (Ethosuximide Oral Solution); Ziagen; Zyvox; Zymar(Gatifloxacin Ophthalmic Solution); Zymaxid (Gatifloxacin OphthalmicSolution).

Drug Classes

5-alpha-reductase inhibitors; 5-aminosalicylates; 5HT3 receptorantagonists; adamantane antivirals; adrenal cortical steroids; adrenalcorticosteroid inhibitors; adrenergic bronchodilators; agents forhypertensive emergencies; agents for pulmonary hypertension; aldosteronereceptor antagonists; alkylating agents; alpha-adrenoreceptorantagonists; alpha-glucosidase inhibitors; alternative medicines;amebicides; aminoglycosides; aminopenicillins; aminosalicylates; amylinanalogs; Analgesic Combinations; Analgesics; androgens and anabolicsteroids; angiotensin converting enzyme inhibitors; angiotensin IIinhibitors; anorectal preparations; anorexiants; antacids;anthelmintics; anti-angiogenic ophthalmic agents; anti-CTLA-4 monoclonalantibodies; anti-infectives; antiadrenergic agents, centrally acting;antiadrenergic agents, peripherally acting; antiandrogens; antianginalagents; antiarrhythmic agents; antiasthmatic combinations;antibiotics/antineoplastics; anticholinergic antiemetics;anticholinergic antiparkinson agents; anticholinergic bronchodilators;anticholinergic chronotropic agents; anticholinergics/antispasmodics;anticoagulants; anticonvulsants; antidepressants; antidiabetic agents;antidiabetic combinations; antidiarrheals; antidiuretic hormones;antidotes; antiemetic/antivertigo agents; antifungals; antigonadotropicagents; antigout agents; antihistamines; antihyperlipidemic agents;antihyperlipidemic combinations; antihypertensive combinations;antihyperuricemic agents; antimalarial agents; antimalarialcombinations; antimalarial quinolines; antimetabolites; antimigraineagents; antineoplastic detoxifying agents; antineoplastic interferons;antineoplastic monoclonal antibodies; antineoplastics; antiparkinsonagents; antiplatelet agents; antipseudomonal penicillins;antipsoriatics; antipsychotics; antirheumatics; antiseptic andgermicides; antithyroid agents; antitoxins and antivenins;antituberculosis agents; antituberculosis combinations; antitussives;antiviral agents; antiviral combinations; antiviral interferons;anxiolytics, sedatives, and hypnotics; aromatase inhibitors; atypicalantipsychotics; azole antifungals; bacterial vaccines; barbiturateanticonvulsants; barbiturates; BCR-ABL tyrosine kinase inhibitors;benzodiazepine anticonvulsants; benzodiazepines; beta-adrenergicblocking agents; beta-lactamase inhibitors; bile acid sequestrants;biologicals; bisphosphonates; bone resorption inhibitors; bronchodilatorcombinations; bronchodilators; calcitonin; calcium channel blockingagents; carbamate anticonvulsants; carbapenems; carbonic anhydraseinhibitor anticonvulsants; carbonic anhydrase inhibitors; cardiacstressing agents; cardioselective beta blockers; cardiovascular agents;catecholamines; CD20 monoclonal antibodies; CD33 monoclonal antibodies;CD52 monoclonal antibodies; central nervous system agents;cephalosporins; cerumenolytics; chelating agents; chemokine receptorantagonist; chloride channel activators; cholesterol absorptioninhibitors; cholinergic agonists; cholinergic muscle stimulants;cholinesterase inhibitors; CNS stimulants; coagulation modifiers; colonystimulating factors; contraceptives; corticotropin; coumarins andindandiones; cox-2 inhibitors; decongestants; dermatological agents;diagnostic radiopharmaceuticals; dibenzazepine anticonvulsants;digestive enzymes; dipeptidyl peptidase 4 inhibitors; diuretics;dopaminergic antiparkinsonism agents; drugs used in alcohol dependence;echinocandins; EGFR inhibitors; estrogen receptor antagonists;estrogens; expectorants; factor Xa inhibitors; fatty acid derivativeanticonvulsants; fibric acid derivatives; first generationcephalosporins; fourth generation cephalosporins; functional boweldisorder agents; gallstone solubilizing agents; gamma-aminobutyric acidanalogs; gamma-aminobutyric acid reuptake inhibitors; gamma-aminobutyricacid transaminase inhibitors; gastrointestinal agents; generalanesthetics; genitourinary tract agents; GI stimulants; glucocorticoids;glucose elevating agents; glycopeptide antibiotics; glycoproteinplatelet inhibitors; glycylcyclines; gonadotropin releasing hormones;gonadotropin-releasing hormone antagonists; gonadotropins; group Iantiarrhythmics; group II antiarrhythmics; group III antiarrhythmics;group IV antiarrhythmics; group V antiarrhythmics; growth hormonereceptor blockers; growth hormones; H. pylori eradication agents; H2antagonists; hematopoietic stem cell mobilizer; heparin antagonists;heparins; HER2 inhibitors; herbal products; histone deacetylaseinhibitors; hormone replacement therapy; hormones;hormones/antineoplastics; hydantoin anticonvulsants; illicit (street)drugs; immune globulins; immunologic agents; immunosuppressive agents;impotence agents; in vivo diagnostic biologicals; incretin mimetics;inhaled anti-infectives; inhaled corticosteroids; inotropic agents;insulin; insulin-like growth factor; integrase strand transferinhibitor; interferons; intravenous nutritional products; iodinatedcontrast media; ionic iodinated contrast media; iron products;ketolides; laxatives; leprostatics; leukotriene modifiers; lincomycinderivatives; lipoglycopeptides; local injectable anesthetics; loopdiuretics; lung surfactants; lymphatic staining agents; lysosomalenzymes; macrolide derivatives; macrolides; magnetic resonance imagingcontrast media; mast cell stabilizers; medical gas; meglitinides;metabolic agents; methylxanthines; mineralocorticoids; minerals andelectrolytes; miscellaneous agents; miscellaneous analgesics;miscellaneous antibiotics; miscellaneous anticonvulsants; miscellaneousantidepressants; miscellaneous antidiabetic agents; miscellaneousantiemetics; miscellaneous antifungals; miscellaneous antihyperlipidemicagents; miscellaneous antimalarials; miscellaneous antineoplastics;miscellaneous antiparkinson agents; miscellaneous antipsychotic agents;miscellaneous antituberculosis agents; miscellaneous antivirals;miscellaneous anxiolytics, sedatives and hypnotics; miscellaneousbiologicals; miscellaneous bone resorption inhibitors; miscellaneouscardiovascular agents; miscellaneous central nervous system agents;miscellaneous coagulation modifiers; miscellaneous diuretics;miscellaneous genitourinary tract agents; miscellaneous GI agents;miscellaneous hormones; miscellaneous metabolic agents; miscellaneousophthalmic agents; miscellaneous otic agents; miscellaneous respiratoryagents; miscellaneous sex hormones; miscellaneous topical agents;miscellaneous uncategorized agents; miscellaneous vaginal agents;mitotic inhibitors; monoamine oxidase inhibitors; monoclonal antibodies;mouth and throat products; mTOR inhibitors; mTOR kinase inhibitors;mucolytics; multikinase inhibitors; muscle relaxants; mydriatics;narcotic analgesic combinations; narcotic analgesics; nasalanti-infectives; nasal antihistamines and decongestants; nasallubricants and irrigations; nasal preparations; nasal steroids; naturalpenicillins; neuraminidase inhibitors; neuromuscular blocking agents;next generation cephalosporins; nicotinic acid derivatives; nitrates;NNRTIs; non-cardioselective beta blockers; non-iodinated contrast media;non-ionic iodinated contrast media; non-sulfonylureas; nonsteroidalanti-inflammatory agents; norepinephrine reuptake inhibitors;norepinephrine-dopamine reuptake inhibitors; nucleoside reversetranscriptase inhibitors (NRTIs); nutraceutical products; nutritionalproducts; ophthalmic anesthetics; ophthalmic anti-infectives; ophthalmicanti-inflammatory agents; ophthalmic antihistamines and decongestants;ophthalmic diagnostic agents; ophthalmic glaucoma agents; ophthalmiclubricants and irrigations; ophthalmic preparations; ophthalmicsteroids; ophthalmic steroids with anti-infectives; ophthalmic surgicalagents; oral nutritional supplements; otic anesthetics; oticanti-infectives; otic preparations; otic steroids; otic steroids withanti-infectives; oxazolidinedione anticonvulsants; parathyroid hormoneand analogs; penicillinase resistant penicillins; penicillins;peripheral opioid receptor antagonists; peripheral vasodilators;peripherally acting antiobesity agents; phenothiazine antiemetics;phenothiazine antipsychotics; phenylpiperazine antidepressants; plasmaexpanders; platelet aggregation inhibitors; platelet-stimulating agents;polyenes; potassium-sparing diuretics; probiotics; progesterone receptormodulators; progestins; prolactin inhibitors; prostaglandin D2antagonists; protease inhibitors; proton pump inhibitors; psoralens;psychotherapeutic agents; psychotherapeutic combinations; purinenucleosides; pyrrolidine anticonvulsants; quinolones; radiocontrastagents; radiologic adjuncts; radiologic agents; radiologic conjugatingagents; radiopharmaceuticals; RANK ligand inhibitors; recombinant humanerythropoietins; renin inhibitors; respiratory agents; respiratoryinhalant products; rifamycin derivatives; salicylates; sclerosingagents; second generation cephalosporins; selective estrogen receptormodulators; selective serotonin reuptake inhibitors;serotonin-norepinephrine reuptake inhibitors; serotoninergicneuroenteric modulators; sex hormone combinations; sex hormones;skeletal muscle relaxant combinations; skeletal muscle relaxants;smoking cessation agents; somatostatin and somatostatin analogs;spermicides; statins; sterile irrigating solutions; streptomycesderivatives; succinimide anticonvulsants; sulfonamides; sulfonylureas;synthetic ovulation stimulants; tetracyclic antidepressants;tetracyclines; therapeutic radiopharmaceuticals; thiazide diuretics;thiazolidinediones; thioxanthenes; third generation cephalosporins;thrombin inhibitors; thrombolytics; thyroid drugs; tocolytic agents;topical acne agents; topical agents; topical anesthetics; topicalanti-infectives; topical antibiotics; topical antifungals; topicalantihistamines; topical antipsoriatics; topical antivirals; topicalastringents; topical debriding agents; topical depigmenting agents;topical emollients; topical keratolytics; topical steroids; topicalsteroids with anti-infectives; toxoids; triazine anticonvulsants;tricyclic antidepressants; trifunctional monoclonal antibodies; tumornecrosis factor (TNF) inhibitors; tyrosine kinase inhibitors; ultrasoundcontrast media; upper respiratory combinations; urea anticonvulsants;urinary anti-infectives; urinary antispasmodics; urinary pH modifiers;uterotonic agents; vaccine; vaccine combinations; vaginalanti-infectives; vaginal preparations; vasodilators; vasopressinantagonists; vasopressors; VEGF/VEGFR inhibitors; viral vaccines;viscosupplementation agents; vitamin and mineral combinations; vitamins

Diagnostic Tests

17-Hydroxyprogesterone; ACE (Angiotensin I converting enzyme);Acetaminophen; Acid phosphatase; ACTH; Activated clotting time;Activated protein C resistance; Adrenocorticotropic hormone (ACTH);Alanine aminotransferase (ALT); Albumin; Aldolase; Aldosterone; Alkalinephosphatase; Alkaline phosphatase (ALP); Alphal-antitrypsin;Alpha-fetoprotein; Alpha-fetoprotien; Ammonia levels; Amylase; ANA(antinuclear antbodies); ANA (antinuclear antibodies);Angiotensin-converting enzyme (ACE); Anion gap; Anticardiolipinantibody; Anticardiolipin antivbodies (ACA); Anti-centromere antibody;Antidiuretic hormone; Anti-DNA; Anti-Dnase-B; Anti-Gliadin antibody;Anti-glomerular basement membrane antibody; Anti-HBc (Hepatitis B coreantibodies; Anti-HBs (Hepatitis B surface antibody; Antiphospholipidantibody; Anti-RNA polymerase; Anti-Smith (Sm) antibodies; Anti-SmoothMuscle antibody; Antistreptolysin O (ASO); Antithrombin III; Anti-Xaactivity; Anti-Xa assay; Apolipoproteins; Arsenic; Aspartateaminotransferase (AST); B12; Basophil; Beta-2-Microglobulin;Beta-hydroxybutyrate; B-HCG; Bilirubin; Bilirubin, direct; Bilirubin,indirect; Bilirubin, total; Bleeding time; Blood gases (arterial); Bloodurea nitrogen (BUN); BUN; BUN (blood urea nitrogen); CA 125; CA 15-3; CA19-9; Calcitonin; Calcium; Calcium (ionized); Carbon monoxide (CO);Carcinoembryonic antigen (CEA); CBC; CEA; CEA (carcinoembryonicantigen); Ceruloplasmin; CH50Chloride; Cholesterol; Cholesterol, HDL;Clot lysis time; Clot retraction time; CMP; CO2; Cold agglutinins;Complement C3; Copper; Corticotrophin releasing hormone (CRH)stimulation test; Cortisol; Cortrosyn stimulation test; C-peptide; CPK(Total); CPK-MB; C-reactive protein; Creatinine; Creatinine kinase (CK);Cryoglobulins; DAT (Direct antiglobulin test); D-Dimer; Dexamethasonesuppression test; DHEA-S; Dilute Russell viper venom; Elliptocytes;Eosinophil; Erythrocyte sedimentation rate (ESR); Estradiol; Estriol;Ethanol; Ethylene glycol; Euglobulin lysis; Factor V Leiden; Factor VIIIinhibitor; Factor VIII level; Ferritin; Fibrin split products;Fibrinogen; Folate; Folate (serum; Fractional excretion of sodium(FENA); FSH (follicle stimulating factor); FTA-ABS; Gamma glutamyltransferase (GGT); Gastrin; GGTP (Gamma glutamyl transferase); Glucose;Growth hormone; Haptoglobin; HBeAg (Hepatitis Be antigen); HBs-Ag(Hepatitis B surface antigen); Helicobacter pylori; Hematocrit;Hematocrit (HCT); Hemoglobin; Hemoglobin A1C; Hemoglobinelectrophoresis; Hepatitis A antibodies; Hepatitis C antibodies; IAT(Indirect antiglobulin test); Immunofixation (IFE); Iron; Lactatedehydrogenase (LDH); Lactic acid (lactate); LDH; LH (Leutinizinghormone; Lipase; Lupus anticoagulant; Lymphocyte; Magnesium; MCH (meancorpuscular hemoglobin; MCHC (mean corpuscular hemoglobinconcentration); MCV (mean corpuscular volume); Methylmalonate; Monocyte;MPV (mean platelet volume); Myoglobin; Neutrophil; Parathyroid hormone(PTH); Phosphorus; Platelets (plt); Potassium; Prealbumin; Prolactin;Prostate specific antigen (PSA); Protein C; Protein S; PSA (prostatespecific antigen); PT (Prothrombin time); PTT (Partial thromboplastintime); RDW (red cell distribution width); Renin; Rennin; Reticulocytecount; reticulocytes; Rheumatoid factor (RF); Sed Rate; Serumglutamic-pyruvic transaminase (SGPT; Serum protein electrophoresis(SPEP); Sodium; T3-resin uptake (T3RU); T4, Free; Thrombin time; Thyroidstimulating hormone (TSH); Thyroxine (T4); Total iron binding capacity(TIBC); Total protein; Transferrin; Transferrin saturation; Triglyceride(TG); Troponin; Uric acid; Vitamin B12; White blood cells (WBC); Widaltest.

Drugs Based on Messenger RNA

A pharmaceutical vessel as previously described containing a fluid iscontemplated in any embodiment, in which the fluid comprises a drugbased on messenger RNA (mRNA), having the structure and characteristicsdisclosed in the following patent documents, which are incorporated byreference in full in this specification, except that none of the claimsare incorporated by reference: US20150086612; WO2013143683;WO2014072061; WO2012072096; US20140030808; US20140178438; US20120195917;US20110311584; WO2012159643; WO2014075788; WO2014075697; WO2014082729.

EXAMPLES PECVD Process for Trilayer Coating

The PECVD trilayer coating described in this specification can beapplied, for example, as follows for a 1 to 5 mL vessel. Two specificexamples are 1 mL thermoplastic resin syringe and a 5 mL thermoplasticresin drug vial. Larger or smaller vessels will call for adjustments inparameters that a person of ordinary skill can carry out in view of theteaching of this specification.

The apparatus used is the PECVD apparatus with rotating quadrupolemagnets as described generally in FIGS. 4-6 and 19-21 ofWO2014085348(A2). The entire text and drawings of WO2014085348(A2) isincorporated here by references.

The general coating parameter ranges, with preferred ranges inparentheses, for a trilayer coating for a 1 mL syringe barrel are shownin the PECVD Trilayer Process General Parameters Table 3 (1 mL syringe)and Table 4 (5 mL vial).

PECVD Trilayer Process General Parameters Table 3 (1 mL syringe)Parameter Units Tie Barrier pH Protective Power W 40-90 140 40-90(60-80) (60-80) TMDSO Flow sccm  1-10 None  1-10 (3-5) (3-5) HMDSO Flowsccm None 1.56 None O₂ Flow sccm 0.5-5  20 0.5-5  (1.5-2.5) (1.5-2.5)Argon Flow sccm  40-120 0  40-120 (70-90) (70-90) Ramp Time seconds NoneNone None Deposition seconds 0.1-10  20 0.1-40  Time (1-3) (15-25) TubePressure Torr 0.01-10  0.59 0.01-10  (0.1-1.5) (0.1-1.5)

PECVD Trilayer Process General Parameters Table 4 (5 mL vial) ParameterUnits Adhesion Barrier Protection Power W 40-90 140 40-90 (60-80)(60-80) TMDSO sccm  1-10 None  1-10 Flow (3-5) (3-5) HMDSO sccm None1.56 None Flow O₂ Flow sccm 0.5-5  20 0.5-5  (1.5-2.5) (1.5-2.5) ArgonFlow sccm  40-120 0  40-120 (70-90) (70-90) Ramp Time seconds None NoneNone Deposition seconds 0.1-10  20 0.1-40  Time (1-3) (15-25) Tube Torr0.01-10  0.59 0.01-10  Pressure (0.1-1.5) (0.1-1.5)

Example 1

Examples of specific coating parameters that have been used for a 1 mLsyringe and 5 mL vial are shown in the PECVD Trilayer Process SpecificParameters Tables 5 (1 mL syringe) and 6 (5 mL vial):

PECVD Trilayer Process Specific Parameters Table 5 (1 mL syringe)Parameter Units Tie Barrier Protection Power W 70 140 70 TMDSO sccm 4None  4 Flow HMDSO sccm None 1.56 None Flow O₂ Flow sccm 2 20  2 ArgonFlow sccm 80 0 80 Ramp Time seconds None None None Deposition seconds2.5 20 10 Time Tube Torr 1 0.59  1 Pressure

PECVD Trilayer Process Specific Parameters Table 6 (5 mL vial) ParameterUnits Adhesion Barrier Protection Power W 20 40 20 TMDSO sccm 2 0 2 FlowHMDSO sccm 0 3 0 Flow O₂ Flow sccm 1 50 1 Argon Flow sccm 20 0 20 RampTime seconds 0 2 2 Deposition seconds 2.5 10 10 Time Tube Torr 0.85 1.290.85 Pressure

The O-parameter and N-parameter values for the pH protective coating orlayer applied to the 1 mL syringe as described above are 0.34 and 0.55,respectively.

The O-parameter and N-parameter values for the pH protective coating orlayer applied to the 5 mL vial are 0.24 and 0.63, respectively.

Example 2

Referring to FIG. 7 and Table 7, Example 2, the thickness uniformity atfour different points along the length of a 1 mL syringe with a stakedneedle (present during PECVD deposition) and the indicated trilayercoating (avg. thicknesses: 38 nm adhesion or tie coating or layer; 55 nmbarrier coating or layer, 273 nm pH protective coating or layer) isshown. The table shows individual layer thicknesses at the four markedpoints, showing adequate thickness of each layer at each point along thehigh profile syringe barrel.

TABLE 7 Example 2 Adhesion Layer Barrier Layer pH Protection LayerSyringe Thickness Thickness Thickness Location (nm) (nm) (nm) 1 46 75343 2 38 55 273 3 86 47 493 4 42 25 287

Referring to FIG. 8, the plot maps the coating thickness over theportion of the cylindrical inner surface of the barrel shown in FIG. 7,as though unrolled to form a rectangle. The overall range of thicknessof the trilayer coating is 572 plus or minus 89 nm.

FIG. 9 is a photomicrograph showing a cross-section of the trilayercoating on a COP syringe substrate at the point 2 shown in FIG. 7.

A syringe having a coating similar to the trilayer coating of FIGS. 7-9is tested for shelf life, using the silicon dissolution andextrapolation method described in this specification, compared tosyringes having a bilayer coating (similar to the trilayer coatingexcept lacking the tie coating or layer) and a monolayer coating whichis just the pH protective coating or layer directly applied to thethermoplastic barrel of the syringe, with no barrier layer. The testsolution was a 0.2% Tween, pH 8 phosphate buffer. The extrapolated shelflives of the monolayer and trilayer coatings were similar and verylong—on the order of 14 years. The shelf life of the syringes having abilayer coating were much lower—less than two years. In other words, thepresence of a barrier layer under the pH protective layer shortened theshelf life of the coating substantially, but the shelf life was restoredby providing a tie coating or layer under the barrier layer, sandwichingthe barrier coating or layer with respective SiO_(x)C_(y) layers. Thebarrier layer is necessary to establish a gas barrier, so the monolayercoating would not be expected to provide adequate gas barrier propertiesby itself.

Example 3

FIG. 10 shows a trilayer coating distribution for another syringe,showing very little variation in coating thickness, with the greatmajority of the surface coated between 150 and 200 nm thickness of thetrilayer, with only a small proportion of the container coated with lessthan 150 nm of the trilayer.

Example 4

The Vial Coating Distribution Table 8 shows the breakdown of coatingthickness (nm) by vial location for a 5 mL vial, illustrated in FIG. 12,which is much shorter in relation to its inner diameter and thus easierto coat uniformly, showing very little variation in coating thickness,with the great majority of the surface coated between 150 and 250 nmthickness of the trilayer, with only a small proportion of the containercoated with between 50 and 150 nm of the trilayer.

Vial Coating Distribution Table 8 Vial Total Location Adhesion BarrierProtection Trilayer, nm 1 13 29 77 119 2 14 21 58 93 3 25 37 115 177 435 49 158 242 5 39 49 161 249 6 33 45 148 226 7 31 29 153 213 8 48 16218 282 9 33 53 155 241 10 31 29 150 210 Average 30 36 139 205

Example 5

FIG. 13 is a visual test result showing the integrity of the trilayervial coating described above. The three 5 mL cyclic olefin polymer (COC)vials of FIGS. 13 and 14 were respectively:

-   -   uncoated (left vial),    -   coated with the bilayer coating described in this specification        (a barrier coating or layer plus a pH protective coating or        layer—the second and third components of the trilayer coating)        (center vial); and    -   coated with the trilayer coating as described above (right        vial).

The three vials were each exposed to 1 N potassium hydroxide for fourhours, then exposed for 24 hours to a ruthenium oxide (RuO4) stain thatdarkens any exposed part of the thermoplastic vial unprotected by thecoatings. The high pH potassium hydroxide exposure erodes any exposedpart of the barrier coating or layer at a substantial rate, greatlyreduced, however by an intact pH protective coating or layer. Inparticular, the high pH exposure opens up any pinholes in the coatingsystem. As FIG. 13 shows, the uncoated vial is completely black, showingthe absence of any effective coating. The bilayer coating was mostlyintact under the treatment conditions, but on microscopic inspection hasmany pinholes (illustrated by FIG. 14) where the ruthenium stain reachedthe thermoplastic substrate through the coating. The overall appearanceof the bilayer coating clearly shows visible “soiled” areas where thestain penetrated. The trilayer coating, however, protected the entirevial against penetration of the stain, and the illustrated vial remainsclear after treatment. This is believed to be the result of sandwichingthe barrier coating or layer between two layers of SiO_(x)C_(y), whichboth protects the barrier layer against direct etching and againstundercutting and removal of flakes of the barrier layer.

Protocol for Total Silicon Measurement

This protocol is used to determine the total amount of silicon coatingspresent on the entire vessel wall. A supply of 0.1 N potassium hydroxide(KOH) aqueous solution is prepared, taking care to avoid contact betweenthe solution or ingredients and glass. The water used is purified water,18 MΩ quality. A Perkin Elmer Optima Model 7300DV ICP-OES instrument isused for the measurement except as otherwise indicated.

Each device (vial, syringe, tube, or the like) to be tested and its capand crimp (in the case of a vial) or other closure are weighed empty to0.001 g, then filled completely with the KOH solution (with noheadspace), capped, crimped, and reweighed to 0.001 g. In a digestionstep, each vial is placed in an autoclave oven (liquid cycle) at 121° C.for 1 hour. The digestion step is carried out to quantitatively removethe silicon coatings from the vessel wall into the KOH solution. Afterthis digestion step, the vials are removed from the autoclave oven andallowed to cool to room temperature. The contents of the vials aretransferred into ICP tubes. The total Si concentration is run on eachsolution by ICP/OES following the operating procedure for the ICP/OES.

The total Si concentration is reported as parts per billion of Si in theKOH solution. This concentration represents the total amount of siliconcoatings that were on the vessel wall before the digestion step was usedto remove it.

The total Si concentration can also be determined for fewer than all thesilicon layers on the vessel, as when an SiOx barrier layer is applied,an SiOxCy second layer (for example, a lubricity layer or a primercoating or layer) is then applied, and it is desired to know the totalsilicon concentration of just the SiOxCy layer. This determination ismade by preparing two sets of vessels, one set to which only the SiOxlayer is applied and the other set to which the same SiOx layer isapplied, followed by the SiOxCy layer or other layers of interest. Thetotal Si concentration for each set of vessels is determined in the samemanner as described above. The difference between the two Siconcentrations is the total Si concentration of the SiO_(x)C_(y) secondlayer.

Protocol for Measuring Dissolved Silicon in a Vessel

In some of the working examples, the amount of silicon dissolved fromthe wall of the vessel by a test solution is determined, in parts perbillion (ppb), for example to evaluate the dissolution rate of the testsolution. This determination of dissolved silicon is made by storing thetest solution in a vessel provided with an SiO_(x) and/or SiO_(x)C_(y)coating or layer under test conditions, then removing a sample of thesolution from the vessel and testing the Si concentration of the sample.The test is done in the same manner as the Protocol for Total SiliconMeasurement, except that the digestion step of that protocol is replacedby storage of the test solution in the vessel as described in thisprotocol. The total Si concentration is reported as parts per billion ofSi in the test solution

Protocol for Determining Average Dissolution Rate

The average dissolution rates reported in the working examples aredetermined as follows. A series of test vessels having a known totalsilicon measurement are filled with the desired test solution analogousto the manner of filling the vials with the KOH solution in the Protocolfor Total Silicon Measurement. (The test solution can be aphysiologically inactive test solution as employed in the presentworking examples or a physiologically active pharmaceutical preparationintended to be stored in the vessels to form a pharmaceutical package).The test solution is stored in respective vessels for several differentamounts of time, then analyzed for the Si concentration in parts perbillion in the test solution for each storage time. The respectivestorage times and Si concentrations are then plotted. The plots arestudied to find a series of substantially linear points having thesteepest slope.

The plot of dissolution amount (ppb Si) versus days decreases in slopewith time, even though it does not appear that the Si layer has beenfully digested by the test solution.

For the PC194 test data in Table 9, linear plots of dissolution versustime data are prepared by using a least squares linear regressionprogram to find a linear plot corresponding to the first five datapoints of each of the experimental plots. The slope of each linear plotis then determined and reported as representing the average dissolutionrate applicable to the test, measured in parts per billion of Sidissolved in the test solution per unit of time.

TABLE 9 OMCTS Argon O₂ Total Si Average Flow Flow Flow Plasma (ppb)Calculated Rate of Rate Rate Rate Power Duration W/FM (OMCTS) Shelf-lifeDissolution Sample (sccm) (sccm) (sccm) (W) (sec) (kJ/kg) layer) (days)(ppb/day) Si Dissolution @ pH 8/23° C./ Process Parameters 0.02%Tween ®-80 PC194 0.5 20 0.5 150 20 1223335 73660 21045 3.5 018 1.0 200.5 18 15 77157 42982 1330 32.3 Si Dissolution @ pH 8/23° C./ ProcessParameters 0.2% Tween ®-80 PC194 0.5 20 0.5 150 20 1223335 73660 387681.9 018 1.0 20 0.5 18 15 77157 42982 665 64.6 048 4 80 2 35 20 3750756520 1074 52.62 Si Dissolution @ pH 8/40° C./ Process Parameters 0.02%Tween ®-80 PC194 0.5 20 0.5 150 20 1223335 73660 8184 9 018 1.0 20 0.518 15 77157 42982 511 84 Si Dissolution @ pH 8/40° C./ ProcessParameters 0.2% Tween ®-80 PC194 0.5 20 0.5 150 20 1223335 73660 14732 5018 1.0 20 0.5 18 15 77157 42982 255 168

Protocol for Determining Calculated Shelf Life

The calculated shelf life values reported in the working examples aredetermined by extrapolation of the total silicon measurements andaverage dissolution rates, respectively determined as described in theProtocol for Total Silicon Measurement and the Protocol for DeterminingAverage Dissolution Rate. The assumption is made that under theindicated storage conditions the SiO_(x)C_(y) primer coating or layerwill be removed at the average dissolution rate until the coating isentirely removed. Thus, the total silicon measurement for the vessel,divided by the dissolution rate, gives the period of time required forthe test solution to totally dissolve the SiO_(x)C_(y) coating. Thisperiod of time is reported as the calculated shelf life. Unlikecommercial shelf life calculations, no safety factor is calculated.Instead, the calculated shelf life is the calculated time to failure.

It should be understood that because the plot of ppb Si versus hoursdecreases in slope with time, an extrapolation from relatively shortmeasurement times to relatively long calculated shelf lives is believedto be a “worst case” test that tends to underestimate the calculatedshelf life actually obtainable.

1. A vessel comprising: a thermoplastic wall: defining a lumen, havingan interior surface facing the lumen, and having a first oxygentransmission rate respecting ingress of oxygen; a coating set on theinterior surface, comprising: optionally, a tie coating or layer havingan interior surface facing the lumen and an outer surface facing thewall interior surface; a barrier coating or layer having an outersurface facing the wall interior surface and, if present, the interiorsurface of the tie coating or layer; and a pH protective coating orlayer having an interior surface facing the lumen and an outer surfacefacing the interior surface of the barrier coating or layer; in whichthe barrier coating or layer is effective to provide a second oxygentransmission rate lower than the first oxygen transmission rate; a fluidhaving a pH from 3 to 9 contained in the lumen; and a closure closingthe vessel to provide a closed pharmaceutical package; in which thecoating set on the interior surface is effective to maintain the secondoxygen transmission rate lower than the first oxygen transmission ratefor at least six months of contact between the fluid in the lumen andthe pH protective coating or layer.
 2. A vessel comprising: athermoplastic wall: defining a lumen, having an interior surface facingthe lumen, and having a first oxygen transmission rate respectingingress of oxygen; a coating set on the interior surface, comprising:optionally, a tie coating or layer having an interior surface facing thelumen and an outer surface facing the wall interior surface; a barriercoating or layer having an outer surface facing the wall interiorsurface and, if present, the interior surface of the tie coating orlayer; and a pH protective coating or layer having an interior surfacefacing the lumen and an outer surface facing the interior surface of thebarrier coating or layer; in which the barrier coating or layer iseffective to provide a second oxygen transmission rate lower than thefirst oxygen transmission rate; in which the coating set on the interiorsurface is effective to maintain the second oxygen transmission ratelower than the first oxygen transmission rate for at least six months ofcontact between a fluid in the lumen having a pH from 3 to 9 and the pHprotective coating or layer.
 3. The vessel of claim 1, in which thethermoplastic wall comprises a polyester, polyethylene terephthalate(PET), polyethylene naphthalate (PEN); a polyolefin, cyclic olefinpolymer (COP), cyclic olefin copolymer (COC), polypropylene (PP), or apolycarbonate.
 4. The vessel of claim 1, in which the vessel comprises asample collection tube, a syringe barrel, a vial, a blister package, anampoule, a cartridge, an injection pen, a bottle, a pouch, a pump, asprayer, a stopper, a needle, a plunger, a cap, a stent, a catheter, animplant, a plastic-coated vial, a plastic coated syringe, a plasticcoated ampoule, a plastic coated bottle, or any other type of containeror conduit for a fluid.
 5. The vessel of claim 1, comprising a tiecoating or layer, in which the tie coating or layer is between 5 and 200nm, alternatively between 5 and 100 nm, alternatively 5-20 nm,alternatively between 10 and 100 nm, alternatively between 10 and 50 nmthick.
 6. The vessel of claim 1, in which the barrier coating or layeris from 2 to 1000 nm thick, alternatively from 20 to 200 nm thick,alternatively from 20 to 30 nm thick.
 7. The vessel of claim 1, in whichthe pH protective coating or layer as applied is between 10 and 1000 nmthick, alternatively between 50 and 500 nm thick, alternatively between100 and 200 nm thick.
 8. The vessel of claim 1, comprising a tie coatingor layer, in which the tie coating or layer comprises SiO_(x)C_(y)wherein x is from about 0.5 to about 2.4 and y is from about 0.6 toabout 3
 9. The vessel of claim 1, in which the barrier coating or layercomprises SiO_(x), wherein x is from 1.5 to 2.9
 10. The vessel of claim1, in which the pH protective coating or layer comprises SiO_(x)C_(y),wherein x is from about 0.5 to about 2.4 and y is from about 0.6 toabout 3
 11. The vessel of claim 1, comprising a tie coating or layer, inwhich the tie coating or layer is applied by PECVD.
 12. The vessel ofclaim 1, in which the barrier coating or layer is applied by PECVD. 13.The vessel of claim 1, in which the pH protective coating or layer isapplied by PECVD.
 14. The vessel of claim 1, in which the fluid has a pHfrom 4 to 8, alternatively between 5 and 9, alternatively between 5 and6, alternatively between 6 and 7, alternatively between 7 and 8,alternatively between 8 and 9, and optionally is a 50 mM potassiumphosphate buffer diluted in water for injection, adjusted to pH 8 withconcentrated nitric acid, and containing 0.2 wt. % polysorbate-80surfactant, at 40° C., alternatively a 50 mM sodium citrate bufferadjusted to pH 6 at 20° C., alternatively a 50 mM potassium phosphatebuffer adjusted to pH 7 at 20° C., alternatively a 50 mM potassiumphosphate buffer adjusted to pH 8 at 20° C., alternatively a 50 mM trisbuffer adjusted to pH 9 at 20° C., alternatively a 50 mM potassiumphosphate buffer adjusted to pH 12 at 20° C.
 15. The vessel of claim 1,in which the fluid composition is an aqueous liquid.
 16. The vessel ofclaim 1, in which the calculated shelf life of the vessel (total Si/Sidissolution rate) is more than six months, or more than 1 year, or morethan 18 months, or more than 2 years.
 17. The vessel of claim 1, inwhich the fluid contained in the lumen has a pH between 5 and 9; whereinthe calculated shelf life of the package is more than six months at astorage temperature of 4° C.
 18. The vessel of claim 1, in which thefluid comprises one or more Inhalation Anesthetics, Injectable Drugs,Liquid Drugs (Non-Injectable), Drug Classes, or Diagnostic Testsselected from the group consisting of: INHALATION ANESTHETICSAliflurane; Chloroform; Cyclopropane; Desflurane (Suprane); DiethylEther; Enflurane (Ethrane); Ethyl Chloride; Ethylene; Halothane(Fluothane); Isoflurane (Forane, Isoflo); Isopropenyl vinyl ether;Methoxyflurane; methoxyflurane; Methoxypropane; Nitrous Oxide;Roflurane; Sevoflurane (Sevorane, Ultane, Sevoflo); Teflurane;Trichloroethylene; Vinyl Ether; Xenon INJECTABLE DRUGS Ablavar(Gadofosveset Trisodium Injection); Abarelix Depot; Abobotulinumtoxin AInjection (Dysport); ABT-263; ABT-869; ABX-EFG; Accretropin (SomatropinInjection); Acetadote (Acetylcysteine Injection); AcetazolamideInjection (Acetazolamide Injection); Acetylcysteine Injection(Acetadote); Actemra (Tocilizumab Injection); Acthrel (CorticorelinOvine Triflutate for Injection); Actummune; Activase; Acyclovir forInjection (Zovirax Injection); Adacel; Adalimumab; Adenoscan (AdenosineInjection); Adenosine Injection (Adenoscan); Adrenaclick; AdreView(lobenguane I 123 Injection for Intravenous Use); Afluria; Ak-Fluor(Fluorescein Injection); Aldurazyme (Laronidase); Alglucerase Injection(Ceredase); Alkeran Injection (Melphalan Hcl Injection); AllopurinolSodium for Injection (Aloprim); Aloprim (Allopurinol Sodium forInjection); Alprostadil; Alsuma (Sumatriptan Injection); ALTU-238; AminoAcid Injections; Aminosyn; Apidra; Apremilast; Alprostadil Dual ChamberSystem for Injection (Caverject Impulse); AMG 009; AMG 076; AMG 102; AMG108; AMG 114; AMG 162; AMG 220; AMG 221; AMG 222; AMG 223; AMG 317; AMG379; AMG 386; AMG 403; AMG 477; AMG 479; AMG 517; AMG 531; AMG 557; AMG623; AMG 655; AMG 706; AMG 714; AMG 745; AMG 785; AMG 811; AMG 827; AMG837; AMG 853; AMG 951; Amiodarone HCl Injection (Amiodarone HClInjection); Amobarbital Sodium Injection (Amytal Sodium); Amytal Sodium(Amobarbital Sodium Injection); Anakinra; Anti-Abeta; Anti-Beta7;Anti-Beta20; Anti-CD4; Anti-CD20; Anti-CD40; Anti-IFNalpha; Anti-IL13;Anti-OX40L; Anti-oxLDS; Anti-NGF; Anti-NRP1; Arixtra; Amphadase(Hyaluronidase Inj); Ammonul (Sodium Phenylacetate and Sodium BenzoateInjection); Anaprox; Anzemet Injection (Dolasetron Mesylate Injection);Apidra (Insulin Glulisine [rDNA origin] Inj); Apomab; Aranesp(darbepoetin alfa); Argatroban (Argatroban Injection); ArginineHydrochloride Injection (R-Gene 10); Aristocort; Aristospan; ArsenicTrioxide Injection (Trisenox); Articane HCl and Epinephrine Injection(Septocaine); Arzerra (Ofatumumab Injection); Asclera (PolidocanolInjection); Ataluren; Ataluren-DMD; Atenolol Inj (Tenormin I.V.Injection); Atracurium Besylate Injection (Atracurium BesylateInjection); Avastin; Azactam Injection (Aztreonam Injection);Azithromycin (Zithromax Injection); Aztreonam Injection (AzactamInjection); Baclofen Injection (Lioresal Intrathecal); BacteriostaticWater (Bacteriostatic Water for Injection); Baclofen Injection (LioresalIntrathecal); Bal in Oil Ampules (Dimercarprol Injection); BayHepB;BayTet; Benadryl; Bendamustine Hydrochloride Injection (Treanda);Benztropine Mesylate Injection (Cogentin); Betamethasone InjectableSuspension (Celestone Soluspan); Bexxar; Bicillin C-R 900/300(Penicillin G Benzathine and Penicillin G Procaine Injection); Blenoxane(Bleomycin Sulfate Injection); Bleomycin Sulfate Injection (Blenoxane);Boniva Injection (Ibandronate Sodium Injection); Botox Cosmetic(OnabotulinumtoxinA for Injection); BR3-FC; Bravelle (UrofollitropinInjection); Bretylium (Bretylium Tosylate Injection); Brevital Sodium(Methohexital Sodium for Injection); Brethine; Briobacept; BTT-1023;Bupivacaine HCl; Byetta; Ca-DTPA (Pentetate Calcium Trisodium Inj);Cabazitaxel Injection (Jevtana); Caffeine Alkaloid (Caffeine and SodiumBenzoate Injection); Calcijex Injection (Calcitrol); Calcitrol (CalcijexInjection); Calcium Chloride (Calcium Chloride Injection 10%); CalciumDisodium Versenate (Edetate Calcium Disodium Injection); Campath(Altemtuzumab); Camptosar Injection (Irinotecan Hydrochloride);Canakinumab Injection (Ilaris); Capastat Sulfate (Capreomycin forInjection); Capreomycin for Injection (Capastat Sulfate); Cardiolite(Prep kit for Technetium Tc99 Sestamibi for Injection); Carticel;Cathflo; Cefazolin and Dextrose for Injection (Cefazolin Injection);Cefepime Hydrochloride; Cefotaxime; Ceftriaxone; Cerezyme; CarnitorInjection; Caverject; Celestone Soluspan; Celsior; Cerebyx (FosphenytoinSodium Injection); Ceredase (Alglucerase Injection); Ceretec (TechnetiumTc99m Exametazime Injection); Certolizumab; CF-101; ChloramphenicolSodium Succinate (Chloramphenicol Sodium Succinate Injection);Chloramphenicol Sodium Succinate Injection (Chloramphenicol SodiumSuccinate); Cholestagel (Colesevelam HCL); Choriogonadotropin AlfaInjection (Ovidrel); Cimzia; Cisplatin (Cisplatin Injection); Clolar(Clofarabine Injection); Clomiphine Citrate; Clonidine Injection(Duraclon); Cogentin (Benztropine Mesylate Injection); ColistimethateInjection (Coly-Mycin M); Coly-Mycin M (Colistimethate Injection);Compath; Conivaptan Hcl Injection (Vaprisol); Conjugated Estrogens forInjection (Premarin Injection); Copaxone; Corticorelin Ovine Triflutatefor Injection (Acthrel); Corvert (Ibutilide Fumarate Injection); Cubicin(Daptomycin Injection); CF-101; Cyanokit (Hydroxocobalamin forInjection); Cytarabine Liposome Injection (DepoCyt); Cyanocobalamin;Cytovene (ganciclovir); D.H.E. 45; Dacetuzumab; Dacogen (DecitabineInjection); Dalteparin; Dantrium IV (Dantrolene Sodium for Injection);Dantrolene Sodium for Injection (Dantrium IV); Daptomycin Injection(Cubicin); Darbepoietin Alfa; DDAVP Injection (Desmopressin AcetateInjection); Decavax; Decitabine Injection (Dacogen); Dehydrated Alcohol(Dehydrated Alcohol Injection); Denosumab Injection (Prolia);Delatestryl; Delestrogen; Delteparin Sodium; Depacon (Valproate SodiumInjection); Depo Medrol (Methylprednisolone Acetate InjectableSuspension); DepoCyt (Cytarabine Liposome Injection); DepoDur (MorphineSulfate XR Liposome Injection); Desmopressin Acetate Injection (DDAVPInjection); Depo-Estradiol; Depo-Provera 104 mg/ml; Depo-Provera 150mg/ml; Depo-Testosterone; Dexrazoxane for Injection, IntravenousInfusion Only (Totect); Dextrose/Electrolytes; Dextrose and SodiumChloride Inj (Dextrose 5% in 0.9% Sodium Chloride); Dextrose; DiazepamInjection (Diazepam Injection); Digoxin Injection (Lanoxin Injection);Dilaudid-HP (Hydromorphone Hydrochloride Injection); DimercarprolInjection (Bal in Oil Ampules); Diphenhydramine Injection (BenadrylInjection); Dipyridamole Injection (Dipyridamole Injection); DMOAD;Docetaxel for Injection (Taxotere); Dolasetron Mesylate Injection(Anzemet Injection); Doribax (Doripenem for Injection); Doripenem forInjection (Doribax); Doxercalciferol Injection (Hectorol Injection);Doxil (Doxorubicin Hcl Liposome Injection); Doxorubicin Hcl LiposomeInjection (Doxil); Duraclon (Clonidine Injection); Duramorph (MorphineInjection); Dysport (Abobotulinumtoxin A Injection); EcallantideInjection (Kalbitor); EC-Naprosyn (naproxen); Edetate Calcium DisodiumInjection (Calcium Disodium Versenate); Edex (Alprostadil forInjection); Engerix; Edrophonium Injection (Enlon); Eliglustat Tartate;Eloxatin (Oxaliplatin Injection); Emend Injection (FosaprepitantDimeglumine Injection); Enalaprilat Injection (Enalaprilat Injection);Enlon (Edrophonium Injection); Enoxaparin Sodium Injection (Lovenox);Eovist (Gadoxetate Disodium Injection); Enbrel (etanercept); Enoxaparin;Epicel; Epinepherine; Epipen; Epipen Jr.; Epratuzumab; Erbitux;Ertapenem Injection (Invanz); Erythropoieten; Essential Amino AcidInjection (Nephramine); Estradiol Cypionate; Estradiol Valerate;Etanercept; Exenatide Injection (Byetta); Evlotra; Fabrazyme (Adalsidasebeta); Famotidine Injection; FDG (Fludeoxyglucose F 18 Injection);Feraheme (Ferumoxytol Injection); Feridex I.V. (Ferumoxides InjectableSolution); Fertinex; Ferumoxides Injectable Solution (Feridex I.V.);Ferumoxytol Injection (Feraheme); Flagyl Injection (MetronidazoleInjection); Fluarix; Fludara (Fludarabine Phosphate); Fludeoxyglucose F18 Injection (FDG); Fluorescein Injection (Ak-Fluor); Follistim AQCartridge (Follitropin Beta Injection); Follitropin Alfa Injection(Gonal-f RFF); Follitropin Beta Injection (Follistim AQ Cartridge);Folotyn (Pralatrexate Solution for Intravenous Injection); Fondaparinux;Forteo (Teriparatide (rDNA origin) Injection); Fostamatinib;Fosaprepitant Dimeglumine Injection (Emend Injection); Foscarnet SodiumInjection (Foscavir); Foscavir (Foscarnet Sodium Injection);Fosphenytoin Sodium Injection (Cerebyx); Fospropofol Disodium Injection(Lusedra); Fragmin; Fuzeon (enfuvirtide); GA101; Gadobenate DimeglumineInjection (Multihance); Gadofosveset Trisodium Injection (Ablavar);Gadoteridol Injection Solution (ProHance); Gadoversetamide Injection(OptiMARK); Gadoxetate Disodium Injection (Eovist); Ganirelix (GanirelixAcetate Injection); Gardasil; GC1008; GDFD; Gemtuzumab Ozogamicin forInjection (Mylotarg); Genotropin; Gentamicin Injection; GENZ-112638;Golimumab Injection (Simponi Injection); Gonal-f RFF (Follitropin AlfaInjection); Granisetron Hydrochloride (Kytril Injection); GentamicinSulfate; Glatiramer Acetate; Glucagen; Glucagon; HAE1; Haldol(Haloperidol Injection); Havrix; Hectorol Injection (DoxercalciferolInjection); Hedgehog Pathway Inhibitor; Heparin; Herceptin; hG-CSF;Humalog; Human Growth Hormone; Humatrope; HuMax; Humegon; Humira;Humulin; Ibandronate Sodium Injection (Boniva Injection); IbuprofenLysine Injection (NeoProfen); Ibutilide Fumarate Injection (Corvert);Idamycin PFS (Idarubicin Hydrochloride Injection); IdarubicinHydrochloride Injection (Idamycin PFS); Ilaris (Canakinumab Injection);Imipenem and Cilastatin for Injection (Primaxin I.V.); Imitrex;Incobotulinumtoxin A for Injection (Xeomin); Increlex (Mecasermin [rDNAorigin] Injection); Indocin IV (Indomethacin Inj); Indomethacin Inj(Indocin IV); Infanrix; Innohep; Insulin; Insulin Aspart [rDNA origin]Inj (NovoLog); Insulin Glargine [rDNA origin] Injection (Lantus);Insulin Glulisine [rDNA origin] Inj (Apidra); Interferon alfa-2b,Recombinant for Injection (Intron A); Intron A (Interferon alfa-2b,Recombinant for Injection); Invanz (Ertapenem Injection); InvegaSustenna (Paliperidone Palmitate Extended-Release InjectableSuspension); Invirase (saquinavir mesylate); lobenguane I 123 Injectionfor Intravenous Use (AdreView); lopromide Injection (Ultravist);loversol Injection (Optiray Injection); Iplex (Mecasermin Rinfabate[rDNA origin] Injection); Iprivask; Irinotecan Hydrochloride (CamptosarInjection); Iron Sucrose Injection (Venofer); Istodax (Romidepsin forInjection); Itraconazole Injection (Sporanox Injection); Jevtana(Cabazitaxel Injection); Jonexa; Kalbitor (Ecallantide Injection); KCLin D5NS (Potassium Chloride in 5% Dextrose and Sodium ChlorideInjection); KCL in D5W; KCL in NS; Kenalog 10 Injection (TriamcinoloneAcetonide Injectable Suspension); Kepivance (Palifermin); KeppraInjection (Levetiracetam); Keratinocyte; KFG; Kinase Inhibitor; Kineret(Anakinra); Kinlytic (Urokinase Injection); Kinrix; Klonopin(clonazepam); Kytril Injection (Granisetron Hydrochloride); lacosamideTablet and Injection (Vimpat); Lactated Ringer's; Lanoxin Injection(Digoxin Injection); Lansoprazole for Injection (Prevacid I.V.); Lantus;Leucovorin Calcium (Leucovorin Calcium Injection); Lente (L); Leptin;Levemir; Leukine Sargramostim; Leuprolide Acetate; Levothyroxine;Levetiracetam (Keppra Injection); Lovenox; Levocarnitine Injection(Carnitor Injection); Lexiscan (Regadenoson Injection); LioresalIntrathecal (Baclofen Injection); Liraglutide [rDNA] Injection(Victoza); Lovenox (Enoxaparin Sodium Injection); Lucentis (RanibizumabInjection); Lumizyme; Lupron (Leuprolide Acetate Injection); Lusedra(Fospropofol Disodium Injection); Maci; Magnesium Sulfate (MagnesiumSulfate Injection); Mannitol Injection (Mannitol IV); Marcaine(Bupivacaine Hydrochloride and Epinephrine Injection); Maxipime(Cefepime Hydrochloride for Injection); MDP Multidose Kit of TechnetiumInjection (Technetium Tc99m Medronate Injection); Mecasermin [rDNAorigin] Injection (Increlex); Mecasermin Rinfabate [rDNA origin]Injection (Iplex); Melphalan Hcl Injection (Alkeran Injection);Methotrexate; Menactra; Menopur (Menotropins Injection); Menotropins forInjection (Repronex); Methohexital Sodium for Injection (BrevitalSodium); Methyldopate Hydrochloride Injection, Solution (MethyldopateHcl); Methylene Blue (Methylene Blue Injection); MethylprednisoloneAcetate Injectable Suspension (Depo Medrol); MetMab; MetoclopramideInjection (Reglan Injection); Metrodin (Urofollitropin for Injection);Metronidazole Injection (Flagyl Injection); Miacalcin; Midazolam(Midazolam Injection); Mimpara (Cinacalet); Minocin Injection(Minocycline Inj); Minocycline Inj (Minocin Injection); Mipomersen;Mitoxantrone for Injection Concentrate (Novantrone); Morphine Injection(Duramorph); Morphine Sulfate XR Liposome Injection (DepoDur); MorrhuateSodium (Morrhuate Sodium Injection); Motesanib; Mozobil (PlerixaforInjection); Multihance (Gadobenate Dimeglumine Injection); MultipleElectrolytes and Dextrose Injection; Multiple Electrolytes Injection;Mylotarg (Gemtuzumab Ozogamicin for Injection); Myozyme (Alglucosidasealfa); Nafcillin Injection (Nafcillin Sodium); Nafcillin Sodium(Nafcillin Injection); Naltrexone XR Inj (Vivitrol); Naprosyn(naproxen); NeoProfen (Ibuprofen Lysine Injection); Nandrol Decanoate;Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection);NEO-GAA; NeoTect (Technetium Tc 99m Depreotide Injection); Nephramine(Essential Amino Acid Injection); Neulasta (pegfilgrastim); Neupogen(Filgrastim); Novolin; Novolog; NeoRecormon; Neutrexin (TrimetrexateGlucuronate Inj); NPH (N); Nexterone (Amiodarone HCl Injection);Norditropin (Somatropin Injection); Normal Saline (Sodium ChlorideInjection); Novantrone (Mitoxantrone for Injection Concentrate); Novolin70/30 Innolet (70% NPH, Human Insulin Isophane Suspension and 30%Regular, Human Insulin Injection); NovoLog (Insulin Aspart [rDNA origin]Inj); Nplate (romiplostim); Nutropin (Somatropin (rDNA origin) for Inj);Nutropin AQ; Nutropin Depot (Somatropin (rDNA origin) for Inj);Octreotide Acetate Injection (Sandostatin LAR); Ocrelizumab; OfatumumabInjection (Arzerra); Olanzapine Extended Release Injectable Suspension(Zyprexa Relprevv); Omnitarg; Omnitrope (Somatropin [rDNA origin]Injection); Ondansetron Hydrochloride Injection (Zofran Injection);OptiMARK (Gadoversetamide Injection); Optiray Injection (loversolInjection); Orencia; Osmitrol Injection in Aviva (Mannitol Injection inAviva Plastic Vessel); Osmitrol Injection in Viaflex (Mannitol Injectionin Viaflex Plastic Vessel); Osteoprotegrin; Ovidrel (ChoriogonadotropinAlfa Injection); Oxacillin (Oxacillin for Injection); OxaliplatinInjection (Eloxatin); Oxytocin Injection (Pitocin); PaliperidonePalmitate Extended-Release Injectable Suspension (Invega Sustenna);Pamidronate Disodium Injection (Pamidronate Disodium Injection);Panitumumab Injection for Intravenous Use (Vectibix); PapaverineHydrochloride Injection (Papaverine Injection); Papaverine Injection(Papaverine Hydrochloride Injection); Parathyroid Hormone; ParicalcitolInjection Fliptop Vial (Zemplar Injection); PARP Inhibitor; Pediarix;PEGlntron; Peginterferon; Pegfilgrastim; Penicillin G Benzathine andPenicillin G Procaine; Pentetate Calcium Trisodium Inj (Ca-DTPA);Pentetate Zinc Trisodium Injection (Zn-DTPA); Pepcid Injection(Famotidine Injection); Pergonal; Pertuzumab; Phentolamine Mesylate(Phentolamine Mesylate for Injection); Physostigmine Salicylate(Physostigmine Salicylate (injection)); Physostigmine Salicylate(injection) (Physostigmine Salicylate); Piperacillin and TazobactamInjection (Zosyn); Pitocin (Oxytocin Injection); Plasma-Lyte 148(Multiple Electrolytes Inj); Plasma-Lyte 56 and Dextrose (MultipleElectrolytes and Dextrose Injection in Viaflex Plastic Vessel);PlasmaLyte; Plerixafor Injection (Mozobil); Polidocanol Injection(Asclera); Potassium Chloride; Pralatrexate Solution for IntravenousInjection (Folotyn); Pramlintide Acetate Injection (Symlin); PremarinInjection (Conjugated Estrogens for Injection); Prep kit for TechnetiumTc99 Sestamibi for Injection (Cardiolite); Prevacid I.V. (Lansoprazolefor Injection); Primaxin I.V. (Imipenem and Cilastatin for Injection);Prochymal; Procrit; Progesterone; ProHance (Gadoteridol InjectionSolution); Prolia (Denosumab Injection); Promethazine HCl Injection(Promethazine Hydrochloride Injection); Propranolol HydrochlorideInjection (Propranolol Hydrochloride Injection); Quinidine GluconateInjection (Quinidine Injection); Quinidine Injection (QuinidineGluconate Injection); R-Gene 10 (Arginine Hydrochloride Injection);Ranibizumab Injection (Lucentis); Ranitidine Hydrochloride Injection(Zantac Injection); Raptiva; Reclast (Zoledronic Acid Injection);Recombivarix HB; Regadenoson Injection (Lexiscan); Reglan Injection(Metoclopramide Injection); Remicade; Renagel; Renvela (SevelamerCarbonate); Repronex (Menotropins for Injection); Retrovir IV(Zidovudine Injection); rhApo2L/TRAIL; Ringer's and 5% DextroseInjection (Ringers in Dextrose); Ringer's Injection (Ringers Injection);Rituxan; Rituximab; Rocephin (ceftriaxone); Rocuronium Bromide Injection(Zemuron); Roferon-A (interferon alfa-2a); Romazicon (flumazenil);Romidepsin for Injection (Istodax); Saizen (Somatropin Injection);Sandostatin LAR (Octreotide Acetate Injection); Sclerostin Ab; Sensipar(cinacalcet); Sensorcaine (Bupivacaine HCl Injections); Septocaine(Articane HCl and Epinephrine Injection); Serostim LQ (Somatropin (rDNAorigin) Injection); Simponi Injection (Golimumab Injection); SodiumAcetate (Sodium Acetate Injection); Sodium Bicarbonate (SodiumBicarbonate 5% Injection); Sodium Lactate (Sodium Lactate Injection inAVIVA); Sodium Phenylacetate and Sodium Benzoate Injection (Ammonul);Somatropin (rDNA origin) for Inj (Nutropin); Sporanox Injection(Itraconazole Injection); Stelara Injection (Ustekinumab); Stemgen;Sufenta (Sufentanil Citrate Injection); Sufentanil Citrate Injection(Sufenta); Sumavel; Sumatriptan Injection (Alsuma); Symlin; Symlin Pen;Systemic Hedgehog Antagonist; Synvisc-One (Hylan G-F 20 SingleIntra-articular Injection); Tarceva; Taxotere (Docetaxel for Injection);Technetium Tc 99m; Telavancin for Injection (Vibativ); TemsirolimusInjection (Torisel); Tenormin I.V. Injection (Atenolol Inj);Teriparatide (rDNA origin) Injection (Forteo); Testosterone Cypionate;Testosterone Enanthate; Testosterone Propionate; Tev-Tropin (Somatropin,rDNA Origin, for Injection); tgAAC94; Thallous Chloride; Theophylline;Thiotepa (Thiotepa Injection); Thymoglobulin (Anti-Thymocyte Globulin(Rabbit); Thyrogen (Thyrotropin Alfa for Injection); TicarcillinDisodium and Clavulanate Potassium Galaxy (Timentin Injection); TiganInjection (Trimethobenzamide Hydrochloride Injectable); TimentinInjection (Ticarcillin Disodium and Clavulanate Potassium Galaxy);TNKase; Tobramycin Injection (Tobramycin Injection); TocilizumabInjection (Actemra); Torisel (Temsirolimus Injection); Totect(Dexrazoxane for Injection, Intravenous Infusion Only); Trastuzumab-DM1;Travasol (Amino Acids (Injection)); Treanda (Bendamustine HydrochlorideInjection); Trelstar (Triptorelin Pamoate for Injectable Suspension);Triamcinolone Acetonide; Triamcinolone Diacetate; TriamcinoloneHexacetonide Injectable Suspension (Aristospan Injection 20 mg);Triesence (Triamcinolone Acetonide Injectable Suspension);Trimethobenzamide Hydrochloride Injectable (Tigan Injection);Trimetrexate Glucuronate Inj (Neutrexin); Triptorelin Pamoate forInjectable Suspension (Trelstar); Twinject; Trivaris (TriamcinoloneAcetonide Injectable Suspension); Trisenox (Arsenic Trioxide Injection);Twinrix; Typhoid Vi; Ultravist (lopromide Injection); Urofollitropin forInjection (Metrodin); Urokinase Injection (Kinlytic); Ustekinumab(Stelara Injection); Ultralente (U); Valium (diazepam); Valproate SodiumInjection (Depacon); Valtropin (Somatropin Injection); VancomycinHydrochloride (Vancomycin Hydrochloride Injection); VancomycinHydrochloride Injection (Vancomycin Hydrochloride); Vaprisol (ConivaptanHcl Injection); VAQTA; Vasovist (Gadofosveset Trisodium Injection forIntravenous Use); Vectibix (Panitumumab Injection for Intravenous Use);Venofer (Iron Sucrose Injection); Verteporfin Inj (Visudyne); Vibativ(Telavancin for Injection); Victoza (Liraglutide [rDNA] Injection);Vimpat (lacosamide Tablet and Injection); Vinblastine Sulfate(Vinblastine Sulfate Injection); Vincasar PFS (Vincristine SulfateInjection); Victoza; Vincristine Sulfate (Vincristine SulfateInjection); Visudyne (Verteporfin Inj); Vitamin B-12; Vivitrol(Naltrexone XR Inj); Voluven (Hydroxyethyl Starch in Sodium ChlorideInjection); Xeloda; Xenical (orlistat); Xeomin (Incobotulinumtoxin A forInjection); Xolair; Zantac Injection (Ranitidine HydrochlorideInjection); Zemplar Injection (Paricalcitol Injection Fliptop Vial);Zemuron (Rocuronium Bromide Injection); Zenapax (daclizumab); Zevalin;Zidovudine Injection (Retrovir IV); Zithromax Injection (Azithromycin);Zn-DTPA (Pentetate Zinc Trisodium Injection); Zofran Injection(Ondansetron Hydrochloride Injection); Zingo; Zoledronic Acid for Inj(Zometa); Zoledronic Acid Injection (Reclast); Zometa (Zoledronic Acidfor Inj); Zosyn (Piperacillin and Tazobactam Injection); ZyprexaRelprevv (Olanzapine Extended Release Injectable Suspension) LIQUIDDRUGS (NON-INJECTABLE) Abilify; AccuNeb (Albuterol Sulfate InhalationSolution); Actidose Aqua (Activated Charcoal Suspension); ActivatedCharcoal Suspension (Actidose Aqua); Advair; Agenerase Oral Solution(Amprenavir Oral Solution); Akten (Lidocaine Hydrochloride OphthalmicGel); Alamast (Pemirolast Potassium Ophthalmic Solution); Albumin(Human) 5% Solution (Buminate 5%); Albuterol Sulfate InhalationSolution; Alinia; Alocril; Alphagan; Alrex; Alvesco; Amprenavir OralSolution; Analpram-HC; Arformoterol Tartrate Inhalation Solution(Brovana); Aristospan Injection 20 mg (Triamcinolone HexacetonideInjectable Suspension); Asacol; Asmanex; Astepro; Astepro (AzelastineHydrochloride Nasal Spray); Atrovent Nasal Spray (Ipratropium BromideNasal Spray); Atrovent Nasal Spray 0.06; Augmentin ES-600; Azasite(Azithromycin Ophthalmic Solution); Azelaic Acid (Finacea Gel);Azelastine Hydrochloride Nasal Spray (Astepro); Azelex (Azelaic AcidCream); Azopt (Brinzolamide Ophthalmic Suspension); BacteriostaticSaline; Balanced Salt; Bepotastine; Bactroban Nasal; Bactroban;Beclovent; Benzac W; Betimol; Betoptic S; Bepreve; BimatoprostOphthalmic Solution; Bleph 10 (Sulfacetamide Sodium Ophthalmic Solution10%); Brinzolamide Ophthalmic Suspension (Azopt); Bromfenac OphthalmicSolution (Xibrom); Bromhist; Brovana (Arformoterol Tartrate InhalationSolution); Budesonide Inhalation Suspension (Pulmicort Respules); Cambia(Diclofenac Potassium for Oral Solution); Capex; Carac; Carboxine-PSE;Carnitor; Cayston (Aztreonam for Inhalation Solution); Cellcept;Centany; Cerumenex; Ciloxan Ophthalmic Solution (Ciprofloxacin HCLOphthalmic Solution); Ciprodex; Ciprofloxacin HCL Ophthalmic Solution(Ciloxan Ophthalmic Solution); Clemastine Fumarate Syrup (ClemastineFumarate Syrup); CoLyte (PEG Electrolytes Solution); Combiven; Comtan;Condylox; Cordran; Cortisporin Ophthalmic Suspension; Cortisporin OticSuspension; Cromolyn Sodium Inhalation Solution (Intal NebulizerSolution); Cromolyn Sodium Ophthalmic Solution (Opticrom); CrystallineAmino Acid Solution with Electrolytes (Aminosyn Electrolytes); Cutivate;Cuvposa (Glycopyrrolate Oral Solution); Cyanocobalamin (CaloMist NasalSpray); Cyclosporine Oral Solution (Gengraf Oral Solution); Cyclogyl;Cysview (Hexaminolevulinate Hydrochloride Intravesical Solution);DermOtic Oil (Fluocinolone Acetonide Oil Ear Drops); DesmopressinAcetate Nasal Spray; DDAVP; Derma-Smoothe/FS; Dexamethasone Intensol;Dianeal Low Calcium; Dianeal PD; Diclofenac Potassium for Oral Solution(Cambia); Didanosine Pediatric Powder for Oral Solution (Videx);Differin; Dilantin 125 (Phenytoin Oral Suspension); Ditropan;Dorzolamide Hydrochloride Ophthalmic Solution (Trusopt); DorzolamideHydrochloride-Timolol Maleate Ophthalmic Solution (Cosopt); DovonexScalp (Calcipotriene Solution); Doxycycline Calcium Oral Suspension(Vibramycin Oral); Efudex; Elaprase (Idursulfase Solution); Elestat(Epinastine HCl Ophthalmic Solution); Elocon; Epinastine HCl OphthalmicSolution (Elestat); Epivir HBV; Epogen (Epoetin alfa); ErythromycinTopical Solution 1.5% (Staticin); Ethiodol (Ethiodized Oil);Ethosuximide Oral Solution (Zarontin Oral Solution); Eurax; Extraneal(Icodextrin Peritoneal Dialysis Solution); Felbatol; Feridex I.V.(Ferumoxides Injectable Solution); Flovent; Floxin Otic (Ofloxacin OticSolution); Flo-Pred (Prednisolone Acetate Oral Suspension); Fluoroplex;Flunisolide Nasal Solution (Flunisolide Nasal Spray 0.025%);Fluorometholone Ophthalmic Suspension (FML); Flurbiprofen SodiumOphthalmic Solution (Ocufen); FML; Foradil; Formoterol FumarateInhalation Solution (Perforomist); Fosamax; Furadantin (NitrofurantoinOral Suspension); Furoxone; Gammagard Liquid (Immune GlobulinIntravenous (Human) 10%); Gantrisin (Acetyl Sulfisoxazole PediatricSuspension); Gatifloxacin Ophthalmic Solution (Zymar); Gengraf OralSolution (Cyclosporine Oral Solution); Glycopyrrolate Oral Solution(Cuvposa); Halcinonide Topical Solution (Halog Solution); Halog Solution(Halcinonide Topical Solution); HEP-LOCK U/P (Preservative-Free HeparinLock Flush Solution); Heparin Lock Flush Solution (Hepflush 10);Hexaminolevulinate Hydrochloride Intravesical Solution (Cysview);Hydrocodone Bitartrate and Acetaminophen Oral Solution (Lortab Elixir);Hydroquinone 3% Topical Solution (Melquin-3 Topical Solution); IAPAntagonist; Isopto; Ipratropium Bromide Nasal Spray (Atrovent NasalSpray); Itraconazole Oral Solution (Sporanox Oral Solution); KetorolacTromethamine Ophthalmic Solution (Acular LS); Kaletra; Lanoxin; Lexiva;Leuprolide Acetate for Depot Suspension (Lupron Depot 11.25 mg);Levobetaxolol Hydrochloride Ophthalmic Suspension (Betaxon);Levocarnitine Tablets, Oral Solution, Sugar-Free (Carnitor);Levofloxacin Ophthalmic Solution 0.5% (Quixin); Lidocaine HCl SterileSolution (Xylocaine MPF Sterile Solution); Lok Pak (Heparin Lock FlushSolution); Lorazepam Intensol; Lortab Elixir (Hydrocodone Bitartrate andAcetaminophen Oral Solution); Lotemax (Loteprednol Etabonate OphthalmicSuspension); Loteprednol Etabonate Ophthalmic Suspension (Alrex); LowCalcium Peritoneal Dialysis Solutions (Dianeal Low Calcium); Lumigan(Bimatoprost Ophthalmic Solution 0.03% for Glaucoma); Lupron Depot 11.25mg (Leuprolide Acetate for Depot Suspension); Megestrol Acetate OralSuspension (Megestrol Acetate Oral Suspension); MEK Inhibitor; Mepron;Mesnex; Mestinon; Mesalamine Rectal Suspension Enema (Rowasa); Melquin-3Topical Solution (Hydroquinone 3% Topical Solution); MetMab;Methyldopate Hcl (Methyldopate Hydrochloride Injection, Solution);Methylin Oral Solution (Methylphenidate HCl Oral Solution 5 mg/5 mL and10 mg/5 mL); Methylprednisolone Acetate Injectable Suspension (DepoMedrol); Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL(Methylin Oral Solution); Methylprednisolone sodium succinate (SoluMedrol); Metipranolol Ophthalmic Solution (Optipranolol); Migranal;Miochol-E (Acetylcholine Chloride Intraocular Solution); Micro-K forLiquid Suspension (Potassium Chloride Extended Release Formulation forLiquid Suspension); Minocin (Minocycline Hydrochloride Oral Suspension);Nasacort; Neomycin and Polymyxin B Sulfates and Hydrocortisone;Nepafenac Ophthalmic Suspension (Nevanac); Nevanac (Nepafenac OphthalmicSuspension); Nitrofurantoin Oral Suspension (Furadantin); Noxafil(Posaconazole Oral Suspension); Nystatin (oral) (Nystatin OralSuspension); Nystatin Oral Suspension (Nystatin (oral)); Ocufen(Flurbiprofen Sodium Ophthalmic Solution); Ofloxacin Ophthalmic Solution(Ofloxacin Ophthalmic Solution); Ofloxacin Otic Solution (Floxin Otic);Olopatadine Hydrochloride Ophthalmic Solution (Pataday); Opticrom(Cromolyn Sodium Ophthalmic Solution); Optipranolol (MetipranololOphthalmic Solution); Patanol; Pediapred; PerioGard; Phenytoin OralSuspension (Dilantin 125); Phisohex; Posaconazole Oral Suspension(Noxafil); Potassium Chloride Extended Release Formulation for LiquidSuspension (Micro-K for Liquid Suspension); Pataday (OlopatadineHydrochloride Ophthalmic Solution); Patanase Nasal Spray (OlopatadineHydrochloride Nasal Spray); PEG Electrolytes Solution (CoLyte);Pemirolast Potassium Ophthalmic Solution (Alamast); Penlac (CiclopiroxTopical Solution); PENNSAID (Diclofenac Sodium Topical Solution);Perforomist (Formoterol Fumarate Inhalation Solution); PeritonealDialysis Solution; Phenylephrine Hydrochloride Ophthalmic Solution(Neo-Synephrine); Phospholine Iodide (Echothiophate Iodide forOphthalmic Solution); Podofilox (Podofilox Topical Solution); Pred Forte(Prednisolone Acetate Ophthalmic Suspension); Pralatrexate Solution forIntravenous Injection (Folotyn); Pred Mild; Prednisone Intensol;Prednisolone Acetate Ophthalmic Suspension (Pred Forte); Prevacid;PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution);ProAir; Proglycem; ProHance (Gadoteridol Injection Solution);Proparacaine Hydrochloride Ophthalmic Solution (Alcaine); Propine;Pulmicort; Pulmozyme; Quixin (Levofloxacin Ophthalmic Solution 0.5%);QVAR; Rapamune; Rebetol; Relacon-HC; Rotarix (Rotavirus Vaccine, Live,Oral Suspension); Rotavirus Vaccine, Live, Oral Suspension (Rotarix);Rowasa (Mesalamine Rectal Suspension Enema); Sabril (Vigabatrin OralSolution); Sacrosidase Oral Solution (Sucraid); Sandimmune; Sepra;Serevent Diskus; Solu Cortef (Hydrocortisone Sodium Succinate); SoluMedrol (Methylprednisolone sodium succinate); Spiriva; Sporanox OralSolution (Itraconazole Oral Solution); Staticin (Erythromycin TopicalSolution 1.5%); Stalevo; Starlix; Sterile HemofiltrationHemodiafiltration Solution (PrismaSol Solution); Stimate; Sucralfate(Carafate Suspension); Sulfacetamide Sodium Ophthalmic Solution 10%(Bleph 10); Synarel Nasal Solution (Nafarelin Acetate Nasal Solution forEndometriosis); Taclonex Scalp (Calcipotriene and BetamethasoneDipropionate Topical Suspension); Tamiflu; Tobi; TobraDex; Tobradex ST(Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05%);Tobramycin/Dexamethasone Ophthalmic Suspension 0.3%/0.05% (Tobradex ST);Timolol; Timoptic; Travatan Z; Treprostinil Inhalation Solution(Tyvaso); Trusopt (Dorzolamide Hydrochloride Ophthalmic Solution);Tyvaso (Treprostinil Inhalation Solution); Ventolin; Vfend; VibramycinOral (Doxycycline Calcium Oral Suspension); Videx (Didanosine PediatricPowder for Oral Solution); Vigabatrin Oral Solution (Sabril); Viokase;Viracept; Viramune; Vitamin K1 (Fluid Colloidal Solution of Vitamin K1);Voltaren Ophthalmic (Diclofenac Sodium Ophthalmic Solution); ZarontinOral Solution (Ethosuximide Oral Solution); Ziagen; Zyvox; Zymar(Gatifloxacin Ophthalmic Solution); Zymaxid (Gatifloxacin OphthalmicSolution). DRUG CLASSES 5-alpha-reductase inhibitors;5-aminosalicylates; 5HT3 receptor antagonists; adamantane antivirals;adrenal cortical steroids; adrenal corticosteroid inhibitors; adrenergicbronchodilators; agents for hypertensive emergencies; agents forpulmonary hypertension; aldosterone receptor antagonists; alkylatingagents; alpha-adrenoreceptor antagonists; alpha-glucosidase inhibitors;alternative medicines; amebicides; aminoglycosides; aminopenicillins;aminosalicylates; amylin analogs; Analgesic Combinations; Analgesics;androgens and anabolic steroids; angiotensin converting enzymeinhibitors; angiotensin II inhibitors; anorectal preparations;anorexiants; antacids; anthelmintics; anti-angiogenic ophthalmic agents;anti-CTLA-4 monoclonal antibodies; anti-infectives; antiadrenergicagents, centrally acting; antiadrenergic agents, peripherally acting;antiandrogens; antianginal agents; antiarrhythmic agents; antiasthmaticcombinations; antibiotics/antineoplastics; anticholinergic antiemetics;anticholinergic antiparkinson agents; anticholinergic bronchodilators;anticholinergic chronotropic agents; anticholinergics/antispasmodics;anticoagulants; anticonvulsants; antidepressants; antidiabetic agents;antidiabetic combinations; antidiarrheals; antidiuretic hormones;antidotes; antiemetic/antivertigo agents; antifungals; antigonadotropicagents; antigout agents; antihistamines; antihyperlipidemic agents;antihyperlipidemic combinations; antihypertensive combinations;antihyperuricemic agents; antimalarial agents; antimalarialcombinations; antimalarial quinolines; antimetabolites; antimigraineagents; antineoplastic detoxifying agents; antineoplastic interferons;antineoplastic monoclonal antibodies; antineoplastics; antiparkinsonagents; antiplatelet agents; antipseudomonal penicillins;antipsoriatics; antipsychotics; antirheumatics; antiseptic andgermicides; antithyroid agents; antitoxins and antivenins;antituberculosis agents; antituberculosis combinations; antitussives;antiviral agents; antiviral combinations; antiviral interferons;anxiolytics, sedatives, and hypnotics; aromatase inhibitors; atypicalantipsychotics; azole antifungals; bacterial vaccines; barbiturateanticonvulsants; barbiturates; BCR-ABL tyrosine kinase inhibitors;benzodiazepine anticonvulsants; benzodiazepines; beta-adrenergicblocking agents; beta-lactamase inhibitors; bile acid sequestrants;biologicals; bisphosphonates; bone resorption inhibitors; bronchodilatorcombinations; bronchodilators; calcitonin; calcium channel blockingagents; carbamate anticonvulsants; carbapenems; carbonic anhydraseinhibitor anticonvulsants; carbonic anhydrase inhibitors; cardiacstressing agents; cardioselective beta blockers; cardiovascular agents;catecholamines; CD20 monoclonal antibodies; CD33 monoclonal antibodies;CD52 monoclonal antibodies; central nervous system agents;cephalosporins; cerumenolytics; chelating agents; chemokine receptorantagonist; chloride channel activators; cholesterol absorptioninhibitors; cholinergic agonists; cholinergic muscle stimulants;cholinesterase inhibitors; CNS stimulants; coagulation modifiers; colonystimulating factors; contraceptives; corticotropin; coumarins andindandiones; cox-2 inhibitors; decongestants; dermatological agents;diagnostic radiopharmaceuticals; dibenzazepine anticonvulsants;digestive enzymes; dipeptidyl peptidase 4 inhibitors; diuretics;dopaminergic antiparkinsonism agents; drugs used in alcohol dependence;echinocandins; EGFR inhibitors; estrogen receptor antagonists;estrogens; expectorants; factor Xa inhibitors; fatty acid derivativeanticonvulsants; fibric acid derivatives; first generationcephalosporins; fourth generation cephalosporins; functional boweldisorder agents; gallstone solubilizing agents; gamma-aminobutyric acidanalogs; gamma-aminobutyric acid reuptake inhibitors; gamma-aminobutyricacid transaminase inhibitors; gastrointestinal agents; generalanesthetics; genitourinary tract agents; GI stimulants; glucocorticoids;glucose elevating agents; glycopeptide antibiotics; glycoproteinplatelet inhibitors; glycylcyclines; gonadotropin releasing hormones;gonadotropin-releasing hormone antagonists; gonadotropins; group Iantiarrhythmics; group II antiarrhythmics; group III antiarrhythmics;group IV antiarrhythmics; group V antiarrhythmics; growth hormonereceptor blockers; growth hormones; H. pylori eradication agents; H2antagonists; hematopoietic stem cell mobilizer; heparin antagonists;heparins; HER2 inhibitors; herbal products; histone deacetylaseinhibitors; hormone replacement therapy; hormones;hormones/antineoplastics; hydantoin anticonvulsants; illicit (street)drugs; immune globulins; immunologic agents; immunosuppressive agents;impotence agents; in vivo diagnostic biologicals; incretin mimetics;inhaled anti-infectives; inhaled corticosteroids; inotropic agents;insulin; insulin-like growth factor; integrase strand transferinhibitor; interferons; intravenous nutritional products; iodinatedcontrast media; ionic iodinated contrast media; iron products;ketolides; laxatives; leprostatics; leukotriene modifiers; lincomycinderivatives; lipoglycopeptides; local injectable anesthetics; loopdiuretics; lung surfactants; lymphatic staining agents; lysosomalenzymes; macrolide derivatives; macrolides; magnetic resonance imagingcontrast media; mast cell stabilizers; medical gas; meglitinides;metabolic agents; methylxanthines; mineralocorticoids; minerals andelectrolytes; miscellaneous agents; miscellaneous analgesics;miscellaneous antibiotics; miscellaneous anticonvulsants; miscellaneousantidepressants; miscellaneous antidiabetic agents; miscellaneousantiemetics; miscellaneous antifungals; miscellaneous antihyperlipidemicagents; miscellaneous antimalarials; miscellaneous antineoplastics;miscellaneous antiparkinson agents; miscellaneous antipsychotic agents;miscellaneous antituberculosis agents; miscellaneous antivirals;miscellaneous anxiolytics, sedatives and hypnotics; miscellaneousbiologicals; miscellaneous bone resorption inhibitors; miscellaneouscardiovascular agents; miscellaneous central nervous system agents;miscellaneous coagulation modifiers; miscellaneous diuretics;miscellaneous genitourinary tract agents; miscellaneous GI agents;miscellaneous hormones; miscellaneous metabolic agents; miscellaneousophthalmic agents; miscellaneous otic agents; miscellaneous respiratoryagents; miscellaneous sex hormones; miscellaneous topical agents;miscellaneous uncategorized agents; miscellaneous vaginal agents;mitotic inhibitors; monoamine oxidase inhibitors; monoclonal antibodies;mouth and throat products; mTOR inhibitors; mTOR kinase inhibitors;mucolytics; multikinase inhibitors; muscle relaxants; mydriatics;narcotic analgesic combinations; narcotic analgesics; nasalanti-infectives; nasal antihistamines and decongestants; nasallubricants and irrigations; nasal preparations; nasal steroids; naturalpenicillins; neuraminidase inhibitors; neuromuscular blocking agents;next generation cephalosporins; nicotinic acid derivatives; nitrates;NNRTIs; non-cardioselective beta blockers; non-iodinated contrast media;non-ionic iodinated contrast media; non-sulfonylureas; nonsteroidalanti-inflammatory agents; norepinephrine reuptake inhibitors;norepinephrine-dopamine reuptake inhibitors; nucleoside reversetranscriptase inhibitors (NRTIs); nutraceutical products; nutritionalproducts; ophthalmic anesthetics; ophthalmic anti-infectives; ophthalmicanti-inflammatory agents; ophthalmic antihistamines and decongestants;ophthalmic diagnostic agents; ophthalmic glaucoma agents; ophthalmiclubricants and irrigations; ophthalmic preparations; ophthalmicsteroids; ophthalmic steroids with anti-infectives; ophthalmic surgicalagents; oral nutritional supplements; otic anesthetics; oticanti-infectives; otic preparations; otic steroids; otic steroids withanti-infectives; oxazolidinedione anticonvulsants; parathyroid hormoneand analogs; penicillinase resistant penicillins; penicillins;peripheral opioid receptor antagonists; peripheral vasodilators;peripherally acting antiobesity agents; phenothiazine antiemetics;phenothiazine antipsychotics; phenylpiperazine antidepressants; plasmaexpanders; platelet aggregation inhibitors; platelet-stimulating agents;polyenes; potassium-sparing diuretics; probiotics; progesterone receptormodulators; progestins; prolactin inhibitors; prostaglandin D2antagonists; protease inhibitors; proton pump inhibitors; psoralens;psychotherapeutic agents; psychotherapeutic combinations; purinenucleosides; pyrrolidine anticonvulsants; quinolones; radiocontrastagents; radiologic adjuncts; radiologic agents; radiologic conjugatingagents; radiopharmaceuticals; RANK ligand inhibitors; recombinant humanerythropoietins; renin inhibitors; respiratory agents; respiratoryinhalant products; rifamycin derivatives; salicylates; sclerosingagents; second generation cephalosporins; selective estrogen receptormodulators; selective serotonin reuptake inhibitors;serotonin-norepinephrine reuptake inhibitors; serotoninergicneuroenteric modulators; sex hormone combinations; sex hormones;skeletal muscle relaxant combinations; skeletal muscle relaxants;smoking cessation agents; somatostatin and somatostatin analogs;spermicides; statins; sterile irrigating solutions; streptomycesderivatives; succinimide anticonvulsants; sulfonamides; sulfonylureas;synthetic ovulation stimulants; tetracyclic antidepressants;tetracyclines; therapeutic radiopharmaceuticals; thiazide diuretics;thiazolidinediones; thioxanthenes; third generation cephalosporins;thrombin inhibitors; thrombolytics; thyroid drugs; tocolytic agents;topical acne agents; topical agents; topical anesthetics; topicalanti-infectives; topical antibiotics; topical antifungals; topicalantihistamines; topical antipsoriatics; topical antivirals; topicalastringents; topical debriding agents; topical depigmenting agents;topical emollients; topical keratolytics; topical steroids; topicalsteroids with anti-infectives; toxoids; triazine anticonvulsants;tricyclic antidepressants; trifunctional monoclonal antibodies; tumornecrosis factor (TNF) inhibitors; tyrosine kinase inhibitors; ultrasoundcontrast media; upper respiratory combinations; urea anticonvulsants;urinary anti-infectives; urinary antispasmodics; urinary pH modifiers;uterotonic agents; vaccine; vaccine combinations; vaginalanti-infectives; vaginal preparations; vasodilators; vasopressinantagonists; vasopressors; VEGF/VEGFR inhibitors; viral vaccines;viscosupplementation agents; vitamin and mineral combinations; vitaminsDIAGNOSTIC TESTS 17-Hydroxyprogesterone; ACE (Angiotensin I convertingenzyme); Acetaminophen; Acid phosphatase; ACTH; Activated clotting time;Activated protein C resistance; Adrenocorticotropic hormone (ACTH);Alanine aminotransferase (ALT); Albumin; Aldolase; Aldosterone; Alkalinephosphatase; Alkaline phosphatase (ALP); Alphal-antitrypsin;Alpha-fetoprotein; Alpha-fetoprotien; Ammonia levels; Amylase; ANA(antinuclear antbodies); ANA (antinuclear antibodies);Angiotensin-converting enzyme (ACE); Anion gap; Anticardiolipinantibody; Anticardiolipin antivbodies (ACA); Anti-centromere antibody;Antidiuretic hormone; Anti-DNA; Anti-Dnase-B; Anti-Gliadin antibody;Anti-glomerular basement membrane antibody; Anti-HBc (Hepatitis B coreantibodies; Anti-HBs (Hepatitis B surface antibody; Antiphospholipidantibody; Anti-RNA polymerase; Anti-Smith (Sm) antibodies; Anti-SmoothMuscle antibody; Antistreptolysin O (ASO); Antithrombin III; Anti-Xaactivity; Anti-Xa assay; Apolipoproteins; Arsenic; Aspartateaminotransferase (AST); B12; Basophil; Beta-2-Microglobulin;Beta-hydroxybutyrate; B-HCG; Bilirubin; Bilirubin, direct; Bilirubin,indirect; Bilirubin, total; Bleeding time; Blood gases (arterial); Bloodurea nitrogen (BUN); BUN; BUN (blood urea nitrogen); CA 125; CA 15-3; CA19-9; Calcitonin; Calcium; Calcium (ionized); Carbon monoxide (CO);Carcinoembryonic antigen (CEA); CBC; CEA; CEA (carcinoembryonicantigen); Ceruloplasmin; CH50Chloride; Cholesterol; Cholesterol, HDL;Clot lysis time; Clot retraction time; CMP; CO2; Cold agglutinins;Complement C3; Copper; Corticotrophin releasing hormone (CRH)stimulation test; Cortisol; Cortrosyn stimulation test; C-peptide; CPK(Total); CPK-MB; C-reactive protein; Creatinine; Creatinine kinase (CK);Cryoglobulins; DAT (Direct antiglobulin test); D-Dimer; Dexamethasonesuppression test; DHEA-S; Dilute Russell viper venom; Elliptocytes;Eosinophil; Erythrocyte sedimentation rate (ESR); Estradiol; Estriol;Ethanol; Ethylene glycol; Euglobulin lysis; Factor V Leiden; Factor VIIIinhibitor; Factor VIII level; Ferritin; Fibrin split products;Fibrinogen; Folate; Folate (serum; Fractional excretion of sodium(FENA); FSH (follicle stimulating factor); FTA-ABS; Gamma glutamyltransferase (GGT); Gastrin; GGTP (Gamma glutamyl transferase); Glucose;Growth hormone; Haptoglobin; HBeAg (Hepatitis Be antigen); HBs-Ag(Hepatitis B surface antigen); Helicobacter pylori; Hematocrit;Hematocrit (HCT); Hemoglobin; Hemoglobin A1C; Hemoglobinelectrophoresis; Hepatitis A antibodies; Hepatitis C antibodies; IAT(Indirect antiglobulin test); Immunofixation (IFE); Iron; Lactatedehydrogenase (LDH); Lactic acid (lactate); LDH; LH (Leutinizinghormone; Lipase; Lupus anticoagulant; Lymphocyte; Magnesium; MCH (meancorpuscular hemoglobin; MCHC (mean corpuscular hemoglobinconcentration); MCV (mean corpuscular volume); Methylmalonate; Monocyte;MPV (mean platelet volume); Myoglobin; Neutrophil; Parathyroid hormone(PTH); Phosphorus; Platelets (pit); Potassium; Prealbumin; Prolactin;Prostate specific antigen (PSA); Protein C; Protein S; PSA (prostatespecific antigen); PT (Prothrombin time); PTT (Partial thromboplastintime); RDW (red cell distribution width); Renin; Rennin; Reticulocytecount; reticulocytes; Rheumatoid factor (RF); Sed Rate; Serumglutamic-pyruvic transaminase (SGPT; Serum protein electrophoresis(SPEP); Sodium; T3-resin uptake (T3RU); T4, Free; Thrombin time; Thyroidstimulating hormone (TSH); Thyroxine (T4); Total iron binding capacity(TIBC); Total protein; Transferrin; Transferrin saturation; Triglyceride(TG); Troponin; Uric acid; Vitamin B12; White blood cells (WBC); Widaltest.